Treatment of mucopolysaccharidosis type i using complete human glycosylated human α-l-iduronidase (IDUA)

JP2024112876A5Inactive Publication Date: 2024-11-15REGENXBIO INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024079088
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-01-11
Filing Date
2024-05-15
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for mucopolysaccharidosis type I, such as enzyme replacement therapy and hematopoietic stem cell transplantation, are ineffective in addressing central nervous system symptoms and carry significant risks and limitations, particularly in stabilizing neurocognitive decline.

Method used

Delivery of fully human glycosylated α-L-iduronidase (HuGlyIDUA) to the cerebrospinal fluid via gene therapy using viral vectors, creating a permanent depot of transduced cells that secrete the enzyme into the CNS, enabling cross-correction of enzyme defects in recipient cells.

Benefits of technology

This approach effectively crosses the blood-brain barrier, providing continuous enzyme replacement and reducing or halting the progression of CNS symptoms in MPS I, including cognitive decline, by ensuring proper uptake and processing by CNS cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

To provide a treatment method of a patient diagnosed with mucopolysaccharidosis type I (MPS I).SOLUTION: A method includes delivering a therapeutically effective amount of recombinant human α-L-iduronidase (IDUA) produced by human nerve cells to cerebrospinal fluid of a brain of a patient. It is preferable to include applying immunosuppressive treatment to the subject before or simultaneously with a treatment by IDUA, and to continue immunosuppressive treatment thereafter.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application is a joint venture of U.S. Provisional Patent Application No. 62 / 452,769, filed January 31, 2017, and U.S. Provisional Patent Application No. 62 / 452,769, filed April 14, 2017. No. 62 / 485,655 filed on July 6, 2017, No. 62 / 529,366 filed on October 1, 2017 The benefit of the application No. 62 / 579,690 filed on the 31st and No. 62 / 616,234 filed on January 11, 2018. No. 6,393,316, which are incorporated herein by reference in their entireties. (Reference to electronically submitted sequence listing) This application is filed on January 16, 2018, and is directed to a "Sequence_List The distribution filed with the application as a text file named "ing_12656-106-228.txt" The table of contents is incorporated by reference.

[0002] (1. Introduction) The complete human genome was then analyzed by immunohistochemistry and immunohistochemistry (ICC) using a cytoplasmic antibody against human subjects diagnosed with mucopolysaccharidosis type I (MPS I). Compositions and methods for delivering triglyceridized (HuGly) α-L-iduronidase (IDUA) are described. Posted. [Background technology]

[0003] 2. BACKGROUND OF THEINVENTION Mucopolysaccharidosis type I (MPS I) is a rare, debilitating genetic disorder with an estimated incidence of 1 in 100,000 births. It is a sexually inherited disease (Moore D et al., 2008, Orphanet Journal of Rare Diseases 3). SI is required for lysosomal catabolism of the ubiquitous complex polysaccharides, heparan sulfate and dermatan sulfate. It is caused by a deficiency of the enzyme α-l-iduronidase (IDUA). These proteins, called glycosaminoglycans (GAGs), accumulate in the tissues of patients with MPS I, causing the characteristic storage lesions and This leads to a variety of disease sequelae. Patients suffer from short stature, bone and joint deformities, coarsening of facial features, Hepatosplenomegaly, valvular heart disease, obstructive sleep apnea, recurrent upper respiratory tract infections, hearing loss, carpal tunnel syndrome The patient may present with visual impairment due to glaucoma and corneal opacity (Beck M et al., 2014, "The Natural History of MPS I: The natural history of MPS I: global perspectives from the SI records om the MPS I Registry), Genetics in medicine: official journal of the American College of Medical Genetics 16(10):759-765). In addition, many patients suffer from hydrocephalus, spinal cord compression, and The findings are related to the storage of GAGs in the central nervous system, which may include obesity, anxiety, and cognitive impairment in some patients. The symptoms are as follows:

[0004] Patients with MPS I span a wide range of disease severity and CNS involvement. This diversity is , correlates with residual IDUA expression; two mutations that result in loss of expression of active enzyme Patients with nonsense mutations, deletions, and some missense mutations typically Symptoms appear before the age of 2 years and, after an initial period of normal development, invariably show severe cognitive decline (Te Ralato NJ and Cox GF, 2003, Genetics in Medicine: official journal of the Am. Erican College of Medical Genetics 5(4):286-294. This severe form of MPS I is Also called Lar (H) syndrome. At least one abrupt change resulting in the production of small amounts of active IDUA. Patients with the mutation have a reduced-function disorder called Hurler-Scheie (HS) syndrome or Scheie syndrome. These patients may present with symptoms early in childhood or early in life. Not discernible until after 10 years. Generally has a delayed onset and may be less severe, but attenuated Patients with this form of MPS I experience all the same physical characteristics as patients with Hurler syndrome. (Vijay S and Wraith JE, 2005, Acta Paediatrica 94(7):872-877). Patients with attenuated MPS I have a high rate of neurological complications, including spinal cord compression and hydrocephalus. Approximately 30% of patients classified as having attenuated MPS I report cognitive impairment. It has been reported (Beck M et al., 2014, Genetics in medicine: official journal of the American College of Medical Genetics 16(10):759-765).

[0005] Enzyme replacement therapy (ERT) [Aldurazyme® (laronidase)] is a marker for the systemic manifestations of MPS I. It is accepted as a quasi-therapeutic, but does not treat CNS manifestations (de Ru MH et al., 2011, Orphan et Journal of Rare Diseases 6:9; Wraith JE et al., 2007, Pediatrics 120(1): E37 -E46). Hematopoietic stem cell transplantation (HSCT) does affect the neurocognitive symptoms of MPS I, but the procedure is critical. HSCT for MPS I is associated with significant morbidity and mortality of up to 20%. However, even with stable IDUA expression, patients still face neurocognitive decline up to 1 year after HSCT. Therefore, treatment is incomplete (de Ru MH et al., 2011, Orphanet Journal of Rare Diseases). 6:9; Fleming DR et al., 1998, Pediatric Transplantation 2(4):299-304; Boelens JJ et al., 2007, Bone Marrow Transplantation 40(3):225-233; Souillet G et al. , 2003, Bone Marrow Transplantation 31(12):1105-1117; Whitley CB et al., 1993, American Journal of Medical Genetics 46(2):209-218. In patients who were successfully transplanted , intelligence typically remains significantly below normal. Summary of the Invention

[0006] (3. SUMMARY OF THEINVENTION) The present invention includes patients diagnosed with Hurler, Hurler-Scheie or Scheie syndromes. The cerebrospinal fluid (CSF) of the central nervous system of a human subject diagnosed with Mucopolysaccharidosis type I (MPS I), including, but not limited to, Delivery of fully human glycosylated (HuGly) α-L-iduronidase (HuGlyIDUA) to cerebrospinal fluid (CSF) In a preferred embodiment, treatment is via gene therapy - for example, human IDUA (hIDUA). Viral vectors or other DNA expression constructs encoding hIDUA or derivatives of hIDUA. into the CSF of a patient (human subject) diagnosed with MPS I to continuously introduce fully human glycosylation. By generating a permanent depot of transduced cells that delivers gene products to the CNS - achieved HuGlyIDUA is secreted from the depot into the CSF and is endocytosed by cells in the CNS. In cis, they "cross-correct" the enzyme defect in the recipient cell. In an alternative embodiment, HuGlyIDUA is produced in cell culture and used as a therapeutic agent for enzyme replacement therapy ("ERT"). However, gene therapy can be used to treat cancer, for example by injecting an enzyme. This therapeutic approach offers several advantages over ERT: the enzyme can cross the blood-brain barrier, The CNS is not treated by systemic delivery of the enzyme because the CNS cannot be treated by gene therapy of the present invention. Unlike the conventional approach, direct delivery of enzymes to the CNS is not only burdensome but also sensitizing. Repeated injections would be necessary creating a risk of contamination.

[0007] The HuGlyIDUA encoded by the transgene may be selected from the group consisting of, but not limited to, SEQ ID NO: 1, human IDUA (hIDUA) having the amino acid sequence of For example, but not limited to, the orthologue of IDUA shown in FIG. The amino acid substitutions may be selected from non-conserved residues corresponding to the FIG. 3 (Saito et al., 2014, Mol. Genet Metab 111:107-112, Table 1 listing 57 MPS I mutations); or each of Venturi et al., 2002, Human Mutations, vol. 11, no. 1, 2002, incorporated herein by reference in its entirety. #522 Online ("Venturi 2002"), or Bertola et al., 2011, Human Mutation 32: Severe, moderately severe, and moderate reported by E2189-E2210 ("Bertola 2011") or does not contain any of the mutations identified in the attenuated MPS I phenotype. The present invention may include derivatives of hIDUA.

[0008] For example, amino acid substitutions at specific positions in hIDUA are shown in FIG. 2, which is incorporated herein by reference in its entirety. The ortholog reported in Maita et al. (2013, PNAS 110:14628, Figure S8) The corresponding sequence found at that position in the IDUA orthologue shown in The substitutions may be selected from non-conserved amino acid residues as shown in FIG. or deleterious mutations reported in Venturi 2002 or Bertola 2011, supra. The resulting transgene product is then incubated in cell culture for 1 h. In culture or in test animals, in vitro to ensure that the mutation does not impair IDUA function The preferred amino acid substitutions selected can be tested using conventional assays. Deletions or additions can be used in conventional in vitro assays for MPS I in cell culture or animal models. Maintain or increase the enzymatic activity, stability, or half-life of the IDUA tested by the assay. For example, the enzymatic activity of the transgene product should be such that it does not The results were evaluated using a conventional enzyme assay with umbelliferyl α-L-iduronide. (For exemplary IDUA enzyme assays that can be used, see, for example, Hopwood et al., 1979, Clin Chim Acta 92: 257-265; Clements et al., 1985, Eur J Biochem 152: 21-28; and Kakkis et al., 19 94, Prot Exp Purif 5:225-232. The ability to transfect MPS I cells in culture with a viral vector encoding hIDUA or a derivative; or other DNA expression constructs; or by injecting MPS I cells with rHuGlyIDUA or a derivative; and co-culturing with human host cells engineered to secrete IgG1 and IgG2, to correct the defect in MPS I cultured cells. For example, by determining IDUA enzyme activity and / or GAG storage in MPS I cells in culture. The respective Myerowitz and Neufeld, 1981, J. Biol Chem 256: 3044-3048; and Anson et al., 1992, Hum Gene Ther 3: 371-379. (I want to be).

[0009] Animal models for MPS I include mice (see, e.g., Clarke et al., 1997; Hum Mol Genet. 6(4):503-511), hybrid domestic cats (see, e.g., Haskins et al., 1979, Pediatrics 1999, 101:111-112, and tr Res 13(11):1294-97), and some breeds of dogs (see, e.g., Menon et al. 1992, Genomics 14(3):763-768; Shull et al., 1982, Am J Pathol 109(2):244- A canine MPS I model has been described (see references in refs. 248). Hurler syndrome, the most severe form of MPS I, is characterized by a loss of detectable protein. The high gene homology between the IDUA proteins (see the alignment in Figure 2) (see references below) means that hIDUA is functional in animals and that therapeutics involving hIDUA can be tested in these animal models.

[0010] Preferably, the rHuGlyIDUA transgene functions in neuronal and / or glial cells. Expression control elements such as the CB7 promoter (chicken β-actin promoter and and CMV enhancer) and is driven by the vector. Other expression control elements that enhance expression of the transgene (e.g., chicken β-actin inserts) The hIDUA transgene can contain a polyA signal (rabbit β-globin polyA signal). The cDNA constructs were subjected to proper co-translation by transduced CNS cells. al) and post-translational processing (glycosylation and protein sulfation) The coding sequence for such peptides used by CNS cells should be included. For signal peptides: Oligodendrocyte-Myelin Glycoprotein (hOMG) Signal Peptide: [ka] Cellular repressor of E1A stimulated genes 2 (hCREG2) signal peptide: [ka] V-set and transmembrane domain-containing 2B (hVSTM2B) signal peptide: [ka] Protocadherin alpha-1 (hPCADHA1) signal peptide: [ka] ·FAM19A1(TAFA1) signal peptide: [ka] Interleukin-2 signal peptide: [ka] These are possible, but not limited to these. A signal peptide is also referred to herein as a leader sequence or leader peptide. This can be done.

[0011] The recombinant vectors used to deliver the transgenes are expressed in neurons and / or glia. The cells should have tropism for cells of the CNS, including but not limited to cells of the CNS. Vectors can include non-replicating recombinant adeno-associated viral vectors ("rAAV"), particularly Viral vectors having AAV9 or AAVrh10 capsids are preferred. No. 7,906,111, which is incorporated herein by reference. Particularly preferred are capsids having AAV / hu.31 and AAV / hu.32, but are not limited thereto. and AAV variant capsids, each of which is incorporated herein by reference in its entirety. No. 8,628,966, U.S. Pat. No. 8,927,514, and Smith et al., 2014 The AAV variant capsid described by Chatterjee in Mol Ther 22:1625-1634 However, "naked DNA" constructs (see section 5.2) can be used. These vectors are called lentiviral vectors, vaccinia virus vectors or non- Other viral vectors, including but not limited to viral expression vectors, may also be used. It is possible.

[0012] Pharmaceutical compositions suitable for administration to the CSF include a physiologically compatible aqueous buffer, a surfactant, and The formulation comprises a suspension of the rHuGlyIDUA vector in a formulation buffer containing optional excipients. In one embodiment, the pharmaceutical composition is suitable for intrathecal administration. The composition is suitable for intracisternal administration (injection into the cisterna magna). In one embodiment, the pharmaceutical composition is suitable for injection into the subarachnoid space via a C1-2 puncture. The composition is suitable for intraventricular administration. In some embodiments, the pharmaceutical composition is administered by lumbar puncture. It is suitable for administration via the intestine.

[0013] A therapeutically effective dose of the recombinant vector can be administered via intrathecal administration (i.e., intrathecal injection). The recombinant vector is then injected into the CSF to transduce cells of the CNS. This can be achieved in several ways, e.g., intracranially (to This can be achieved by injection into the ventricles (cisterna magna or ventricles), or into the lumbar cisterna. Intracisternal (IC) injection can be performed via CT-guided suboccipital puncture; Injection into the subarachnoid space via C1-2 puncture should be performed if feasible for the patient. or a lumbar puncture (a diagnostic procedure typically performed to collect a sample of CSF) It can be used to access the CSF. Alternatively, it can be administered intracerebroventricularly (ICV) (blood-brain using a technique that does not penetrate the hilum, a more invasive technique used for the delivery of anti-infective or anti-cancer drugs. Alternatively, the recombinant vector can be administered intranasally. may be used to deliver recombinant vectors to the CNS. C of at least 9.25 μg / mL min Use a dose that maintains the patient at a constant concentration or a concentration in the range of 9.25 to 277 μg / mL. It should be used.

[0014] CSF concentrations were determined by directly measuring the concentration of rHuGlyIDUA in CSF fluid obtained via occipital or lumbar puncture. The concentration of rHuGlyIDUA detected in the patient's serum was monitored by In one embodiment, the serum rHuGlyIDUA concentration is 10 A range of ng / mL to 100 ng / mL indicates that the amount of rHuGlyIDUA in the CSF is 1 to 30 mg. In one embodiment, the recombinant vector maintains rHuGlyIDUA in serum at 10 ng / mL to 100 ng / mL. Administer into the CSF in a dose that will sustain the desired therapeutic effect.

[0015] By way of background, human IDUA is translated as a 653 amino acid polypeptide, shown in FIG. N-glycosylation was observed at six potential sites (N110, N190, N336, N372, N415, and N451). The signal sequence is removed and the polypeptide is processed to its mature form in the lysosome. The 75 kDa intracellular precursor is trimmed to 72 kDa over a period of several hours, and finally It takes 4-5 days for IDUA to be processed into a 66 kDa intracellular form. The mannose-6-phosphate receptor (76 kDa or 82 kDa depending on the enzyme) is readily expressed in cells. are exocytosed and processed similarly to the smaller intracellular forms (each of which Myerowitz and Neufeld, 1981, J. Biol Chem 256: 3044-3048; Clements et al., 1989, Biochem J. 259: 199-208; Taylo R et al., 1991, Biochem J. 274: 263-268; and Zhao et al., 1997, J Biol Chem 272 :22758-22765).

[0016] The overall structure of hIDUA consists of three domains: residues 42-396 contain a classical (β / α) triad The TIM barrel domain is formed by the thiol phosphate isomerase (TIM) enzyme; residues 27-42 and 397-545 form the short forming a β-sandwich domain having a helix-loop-helix (482-508); and Residues 546-642 form an Ig-like domain. The last two domains are 541 and C 577 The β-sandwich and Ig-like domains are linked by disulfide bridges between the TIM It is bound to the first, seventh, and eighth α-helices of the barrel. 3) is inserted between the eighth β-strand and the eighth α-helix of the TIM barrel, N-glycosylated N is required for substrate binding and enzyme activity 372 (See Figure 1 and each of its entirety.) Maita et al., 2013, PNAS 110: 14628-146, the contents of which are incorporated herein by reference. See the crystal structure in Saito et al., 2014 Mol Genet Metab 111:107-112. sea ​​bream).

[0017] The present invention is based in part on the following principles: (i) Neurons and glial cells of the CNS undergo glycosylation and endothelial cell death, which are active processes in the CNS. Contains the cellular machinery for post-translational processing of secreted proteins, including tyrosine-O-sulfation The post-translational modifications carried out by human CNS cells are described in their entirety in the following references. For example, the human brain mannose-6-phosphate (M6P) glycoproteome It has been described that the brain contains many more individual isoforms than are found in other tissues. It was noted that the chromosomes contained more proteins than the chromosomes containing mannose-6-phosphorylated proteins. , Sleat et al., 2005, Proteomics 5: 1520-1532 and Sleat, 1996, J Biol Chem 271:19191-98; and the production of secreted tyrosine sulfated glycoproteins by neuronal cells. The literature reporting this is based on Kanan et al., 2009, Exp. Eye Res. 89: 559-567 and Kanan and Al-Ubai See di, 2015 Exp. Eye Res. 133: 126-131. (ii) hIDUA has six asparagine ("N") glycosylation sites, identified in FIG. 1 ( N 110 FT;N 190 V.S.; N 336 T.T.; N 372 NT; N 415 H.T.; N 451 RS). N 372N-glycosylation of Mannose-6-phosphorylation is required for binding and enzymatic activity, and is involved in cellular uptake of the secreted enzyme. N-linked glycosylation sites are required for the translocation and cross-revision of MPS I cells. Although it contains mannose and phosphorylated mannose carbohydrate moieties (Fig. 4), only the secreted form is taken up by cells. (Myerowitz and Neufeld, supra, 1981). The roach was measured by polyacrylamide gel electrophoresis (depending on the assay used). 2,6-sialylated and mannose-6 phosphorylated IDUA glycoprotein of 76-82 kDa The secreted glycosylated / phosphorylated IDUA is a morphogenetic protein of the CNS. It is taken up and correctly processed by non-transduced neurons and glial cells. should be done. (iii) Cellular and intracellular trafficking / uptake of lysosomal proteins is mediated by M6P. Daniel In the literature, Iduronate-2 -Measure the M6P content of secreted proteins, as was done for the sulfatase enzyme. In the presence of inhibitory M6P (e.g., 5 mM), non-neuronal or non-glial cells For example, Daniele et al., 2002, reported that enzyme precursors produced by genetically engineered kidney cells Uptake by the body was at levels close to those of control cells, as shown by Daniele, 2002. Even in the presence of inhibitory M6P, brain cells, e.g. The uptake of enzyme precursors produced by the glial cells was greater than that of control cells. Fourfold higher zymogens were produced by engineered kidney cells in the absence of inhibitory M6P The levels of enzyme activity (i.e., uptake) of Using this assay, it is predicted that the levels of IL-1 produced by brain cells will remain high as previously reported. To predict the M6P content of the enzyme precursors produced, specifically the enzymes produced by different cell types. It is possible to compare the M6P content in the precursor cells of the gene therapy described herein. Roach reported that in such assays, the presence of inhibitory M6P resulted in high levels of neuronal and glioma cells. This should result in continuous secretion of hIDUA which can be taken up by the cytoplasmic cells. (iv) In addition to the N-linked glycosylation sites, hIDUA has N-glycosylation sites required for binding and activity. 3 72 A tyrosine ("Y") sulfation site near the domain containing [ka] (See, e.g., Protein Tyrosine Sulfation, Analysis of the amino acids surrounding the tyrosine residues that are affected by the tyrosine residues in Yang et al., 2015, Molecular Biology. les 20:2138-2164, especially p. 2154. The "Rules" can be summarized as follows: The Y residue has E or D within the +5 to -5 positions from Y, and the -1 position of Y is neutral or acidic. - a neutral charged amino acid, but not a basic amino acid, such as R, K, or H, that disables sulfation Without intending to be bound by any theory, tyrosine sulfated regions Mutations in the IL-1 gene (e.g., W306L) are known to be associated with reduced enzyme activity and disease. Therefore, sulfation of this site in hIDUA may be crucial for activity (Maita et al., 2013). , PNAS 110:14628, pp. 14632-14633). (v) glycosylation of hIDUA by human cells of the CNS to improve stability, half-life, and Glycans are added that can reduce unwanted aggregation of the transgene product. In addition, the glycan added to the HuGlyIDUA of the present invention contains 2,6-sialic acid, Neu5Ac ("NANA"). However, its hydroxylated derivative NeuGc (N-glycolylneuraminic acid, i.e. " Highly processed complex-type biantennary N-glycans that do not incorporate NGNA or Neu5Gc Such glycans contain the 2,6-sialyltransferases required for this post-translational modification. It does not have a transesterase and does not produce bisecting GlcNAc, but it does produce a substitute for Neu5Ac (NANA). In particular, the atypical (and potentially immunogenic) sialic acid Neu5Gc(NGNA) is It is not present in the laronidase produced in additional CHO cells. For example, Dumont et al. Literature, 2016, Critical Rev in Biotech 36(6):1110-1122 (Early online pp. 1-13, p. 5 and Hague et al., 1998, Electrophor 19:2612-2630 ("CHO cell lines are capable of expressing α2,6-sialylated is "phenotypically restricted" with respect to glycosylation due to the lack of glycosylation enzymes In addition, CHO cells react with anti-α-Gal antibodies present in most individuals. They also produce the immunogenic glycan, α-Gal antigen, which can induce anaphylaxis at high concentrations. See, e.g., Bosques, 2010, Nat Biotech 28: 1153-1156. The human glycosylation pattern of HuGlyIDUA reduces the immunogenicity of the transgene product, and Efficacy should be improved. (vi) Tyrosine sulfation of hIDUA, an active post-translational process in human CNS cells, enhances the expression of transgenes. The processing and activity of lysosomal proteins should be improved. The significance of oxidation remains unclear; however, tyrosine sulfation has been shown to be involved in other proteins. This increases the affinity of protein-protein interactions (antibodies and receptors) and enhances the affinity of proteins. It has been shown that proteolytic processing of peptide hormones is enhanced (Moore, 2002). 2003, J Biol. Chem. 278:24243-46; and Bundegaard et al., 1995, EMBO J 14: 3073-7. 9). Tyrosine sulfation, which occurs as the final step in the processing of IDUA, Tyrosine protein sulfotransferase 1 (TPST1), which is responsible for the Gene expression data for PST1 can be accessed at, for example, http: / / www.ebi.ac.uk / gxa / home. (which can be found in the EMBL-EBI Expression Atlas available at http: / / www.embl.org / expressionatlas.html) Such post-translational modifications are at best expressed in the CHO cell product Laronida. Unlike human CNS cells, CHO cells are not secretory cells and They have limited post-translational tyrosine sulfation capacity (see, e.g., Mikkelsen and Ezban, 1991, Biochemistry 30: 1533-1537, especially the discussion on page 1537). (vii) The immunogenicity of the transgene product depends on the immune status of the patient, the structure of the injected protein drug, The efficacy and safety of the treatment may be influenced by a variety of factors, including the dosage and characteristics, route of administration, and duration of treatment. Process-related impurities, such as host cell proteins (HCPs), host cell DNA, and chemical residues, as well as and product-related impurities, e.g., protein degradation products and structural characteristics, e.g., glycosylation, acid The aggregation and agglutination (subvisible particles) of the antibody can act as an adjuvant to enhance the immune response. The amount of process-related and product-related impurities may increase immunogenicity. Manufacturing processes: cell culture, purification, formulation that may affect commercially manufactured IDUA products In gene therapy, proteins are produced in vivo. As a result, there are no process-related impurities and the protein product is produced by recombinant technology. Product-related impurities / degradants associated with the protein produced, e.g., protein aggregates and Protein oxidation is unlikely. Aggregation is associated with, for example, protein production and storage. These include high protein concentrations, surface interactions with manufacturing equipment and vessels, and specific buffer solutions. However, the in vivo expression of the transgene is not consistent with the purification process using the system. In the case of β-lactamase, these conditions that promote aggregation are not present. Oxidation of heptaphan and histidine is associated with protein production and storage, e.g. Stressed cell culture conditions, exposure to metals and air, and in buffers and excipients Proteins expressed in vivo are stressed and However, humans, like most organisms, are equipped with an antioxidant defense system. thereby not only reducing oxidative stress but also repairing and / or reversing oxidation. Therefore, it is unlikely that proteins produced in vivo are in an oxidized form. Both aggregation and oxidation can affect efficacy, PK (clearance), and raise immunogenic concerns. The gene therapy approaches described herein can be used to increase the yield of genomic DNA compared to commercially manufactured products. The antibody should continually secrete hIDUA, which has reduced immunogenicity compared to the antibody.

[0018] For the reasons mentioned above, production of HuGlyIDUA is not associated with, for example, MPS I disease (Hurler, Hurler-Schmidt, C of a patient (human subject) diagnosed with glaucoma or glaucoma (including, but not limited to, glaucoma or glaucoma) SFs were administered a viral vector or other DNA expression construct encoding HuGlyIDUA. , fully human glycosylated, mannose-6-phosphate dehydrogenase secreted by transduced CNS cells By creating a durable depot in the CNS that provides a constant supply of oxidized and sulfated transgene products, - A "biobetter" for the treatment of MPS I achieved by gene therapy The HuGlyIDUA transgene product secreted from the depot into the CSF should result in Endocytosed by cells in the CNS, leading to enzymatic defects in MPS I recipient cells This results in "transverse correction."

[0019] All hIDUA molecules produced in gene or protein therapy approaches are complete. It is not essential that the entire glycoprotein be glycosylated and sulfated. The quality population was designed to have sufficient glycosylation (2,6-sialylation and mannose) to demonstrate efficacy. The objective of the gene therapy procedure of the present invention is to The goal of the study was to slow or stop the progression of the disease. Efficacy was measured by improving cognitive function (e.g., cognitive function). prevention or reduction of cognitive decline; disease biomarkers in CSF and / or serum ( and / or increased CSF and / or serum IDUA enzyme activity. Monitoring for signs of inflammation and other safety events. It is also possible.

[0020] As an alternative or adjunct to gene therapy, the rHuGlyIDUA glycoprotein has been developed using recombinant DNA technology. The glycoprotein can be produced in human cell lines by recombinant DNA technology and delivered systemically and / or for ERT. Such recombinant glycoproteins can be administered to patients diagnosed with MPS I in the CSF for Human cell lines that can be used for protein production include, but are not limited to, a few examples: Some examples include HT-22, SK-N-MC, HCN-1A, HCN-2, NT2, SH-SY5y, hNSC11, ReNcell VM, and human embryonic stem cells. Human embryonic kidney 293 cells (HEK293), fibrosarcoma HT-1080, HKB-11, CAP, HuH-7, retinal cell line, PER.C6, or contains RPE (e.g., rHuGlyIDUA glycoprotein, which is incorporated by reference in its entirety). See Dumont et al. for a review of human cell lines that can be used for recombinant production of , 2016, Critical Rev in Biotech 36(6):1110-1122, “Human Cells for Biopharmaceutical Manufacturing.” Human cell lines for biopharmaceutical manufacturing: history, current status, and future prospects Complete glycosylation, especially sialic acid To ensure acid addition and tyrosine sulfation, the cell line used for production was tyrosine-O-sulfated. α-2,6-sialyltransferase (or α-2,3- and α-2,6-sialyltransferase) responsible for the synthesis of The host cells are engineered to co-express the TPST-1 and TPST-2 enzymes, as well as both the TPST-1 and TPST-2 enzymes. This can be strengthened by:

[0021] While delivery of rHuGlyIDUA should minimize immune responses, The most obvious potential source of toxicity is a genetic deficiency of IDUA, and thus a loss of protein and / or Expression in human subjects that are potentially intolerant of the vectors used to deliver the transgene The main cause of death is the development of immunity against the immunized hIDUA protein.

[0022] Thus, in a preferred embodiment, co-treating a patient with immunosuppressive therapy - particularly in the setting of an ID - Suitable for treating patients with severe disease (e.g., Hurler) whose UA levels are close to 0 Tacrolimus or rapamycin (sirolimus) can be combined with, for example, mycophenolic acid. Corticosteroids such as prednisolone and / or methylprednisolone Regimens in combination with steroids or other immunosuppressive regimens used in tissue transplant procedures Immunosuppressive therapy involving zymene can be used. Such immunosuppressive therapy can be used It can be administered during the course of treatment, and in some embodiments, pretreatment with immunosuppressive therapy. Immunosuppressive therapy may be preferred following gene therapy treatment at the discretion of the treating physician. If immune tolerance is induced, the treatment can be continued for 180 days or discontinued. It is possible.

[0023] Combining delivery of HuGlyIDUA to the CSF with delivery of other available therapeutics is contemplated in the methods of the invention. The additional treatment may be administered prior to, simultaneously with, or after the gene therapy treatment. There are available treatments for MPS I that can be used in combination with the gene therapy of the present invention. Treatments include, but are not limited to, laronidase administered systemically or into the CSF. There are enzyme replacement therapies and / or HSCT using Illustrative Embodiments 1. A method for treating a human subject diagnosed with Mucopolysaccharidosis Type I (MPS I), comprising: Therapeutically effective amounts of recombinant human α-L-iduronidase produced by human neuronal cells in cerebrospinal fluid The method further comprises delivering IDUA. 2. A method of treating a human subject diagnosed with MPS I, comprising administering to the cerebrospinal fluid of the brain of the human subject a human granulocyte colony-stimulating antibody. the method comprising delivering a therapeutically effective amount of recombinant human IDUA produced by the human leukocytes. Law. 3. administering immunosuppressive therapy to the subject prior to or concurrently with treatment with human IDUA; and 3. The method of paragraph 1 or 2, further comprising continuing the immunosuppressive treatment thereafter. 4. A method of treating a human subject diagnosed with MPS I, comprising: delivering a therapeutically effective amount of α2,6-sialylated human IDUA to the cerebrospinal fluid of the brain of said human subject. The method comprising: 5. A method of treating a human subject diagnosed with Mucopolysaccharidosis Type I (MPS I), comprising: A therapeutically effective amount of glycosylated hirudin containing no detectable NeuGc in the cerebrospinal fluid of the brain of the human subject. The method further comprises delivering IDUA to a subject. 6. A method of treating a human subject diagnosed with Mucopolysaccharidosis Type I (MPS I), comprising: The therapeutically effective amount of the human subject is free of detectable NeuGc and / or α-Gal antigens in the cerebrospinal fluid of the brain. delivering an amount of glycosylated human IDUA; and administering an immunosuppressant treatment to the subject prior to or concurrently with treatment with the human IDUA, and and continuing immunosuppressive treatment thereafter. 7. A method of treating a human subject diagnosed with Mucopolysaccharidosis Type I (MPS I), comprising: delivering a therapeutically effective amount of human IDUA containing tyrosine sulfation to the cerebrospinal fluid of the brain of the human subject; The method comprising: 8. A method of treating a human subject diagnosed with Mucopolysaccharidosis Type I (MPS I), comprising: administering to the brain of the human subject an expression vector encoding human IDUA, is α2,6-sialylated when expressed from the expression vector in human immortalized neuronal cells. The method comprises administering. 9. A method of treating a human subject diagnosed with Mucopolysaccharidosis Type I (MPS I), comprising: administering to the brain of the human subject an expression vector encoding human IDUA, is glycosylated when expressed from the expression vector in human immortalized neural cells. The method comprises administering said compound, wherein said compound does not contain detectable NeuGc. 10. A method of treating a human subject diagnosed with Mucopolysaccharidosis Type I (MPS I), comprising: administering to the brain of the human subject an expression vector encoding human IDUA, is glycosylated when expressed from the expression vector in human immortalized neural cells. The method comprises administering a subject that is free of detectable NeuGc and / or α-Gal antigens. 11. A method of treating a human subject diagnosed with Mucopolysaccharidosis Type I (MPS I), comprising: administering to the brain of the human subject an expression vector encoding human IDUA, is tyrosine sulfated when expressed from the expression vector in human immortalized neural cells. , said administering. 12. A method of treating a human subject diagnosed with Mucopolysaccharidosis Type I (MPS I), comprising: A therapeutically effective amount of a recombinant nucleotide sequence encoding human IDUA is administered to the cerebrospinal fluid of the brain of the human subject. administering the current vector, thereby producing an IDUA vector that contains α2,6-sialylated glycans; The method comprises administering, wherein a depot is formed that releases the 13. A method of treating a human subject diagnosed with Mucopolysaccharidosis Type I (MPS I), comprising: A therapeutically effective amount of a recombinant nucleotide sequence encoding human IDUA is administered to the cerebrospinal fluid of the brain of the human subject. Administering the current vector, resulting in glycosylation that does not contain detectable NeuGc. The method, comprising the administering step, wherein a depot is formed that releases human IDUA. 14. A method of treating a human subject diagnosed with Mucopolysaccharidosis Type I (MPS I), comprising: A therapeutically effective amount of a recombinant nucleotide sequence encoding human IDUA is administered to the cerebrospinal fluid of the brain of the human subject. and administering the present vector, which results in a vaccine containing detectable NeuGc and / or α-Gal antigens. wherein a depot is formed that releases glycosylated human IDUA that is not glycosylated. The method. 15. A method of treating a human subject diagnosed with Mucopolysaccharidosis Type I (MPS I), comprising: A therapeutically effective amount of a recombinant nucleotide sequence encoding human IDUA is administered to the cerebrospinal fluid of the brain of the human subject. and administering the vector, which results in the release of the IDUA containing tyrosine sulfation. The method further comprises administering, wherein a pore is formed. 16. Prior to or concurrently with the treatment with said human IDUA, (a) tacrolimus and mycophenone (b) rapamycin and mycophenolic acid; or (c) tacrolimus, rapamycin. , and corticosteroids, such as prednisolone and / or methylprednisolone. administering to said subject a combination of 16. The method of any one of paragraphs 3 to 15, further comprising: 17. The method of paragraph 16, wherein the immunosuppressive treatment is discontinued after 180 days. 18. The method of any one of paragraphs 1 to 17, wherein the human IDUA comprises the amino acid sequence of SEQ ID NO:1. Law. 19. Prior to or concurrently with the treatment with said human IDUA, (a) tacrolimus and mycophenone (b) rapamycin and mycophenolic acid; or (c) tacrolimus, rapamycin. , and corticosteroids, such as prednisolone and / or methylprednisolone. and further administering to the subject an immunosuppressive treatment comprising administering to the subject a combination of 19. The method of paragraph 18, comprising: 20. The method of paragraph 19, wherein the immunosuppressive treatment is discontinued after 180 days. 21. The production of said IDUA containing α2,6-sialylated glycans was assayed in cell culture using the human neuronal cell line by transducing the recombinant nucleotide expression vector. 13. The method described in 12. 22. The production of said glycosylated IDUA without detectable NeuGc was assayed using human neuroendocrine disruptors in cell culture. The cell lines are identified by transfection with the recombinant nucleotide expression vector. 14. The method according to paragraph 13. 23. The production of said glycosylated IDUA without detectable NeuGc and / or α-Gal antigens is determined by cell culture. Transducing human neural cell lines in cell culture with the recombinant nucleotide expression vectors. 15. The method of paragraph 14, wherein the method is performed by: 24. The production of said IDUA containing tyrosine sulfation is assayed by recombinant human neuronal cell lines in cell culture. 16. The method according to paragraph 15, wherein the method is confirmed by transfection with a nucleotide expression vector. . 25. Any of paragraphs 21 to 24, in which production is confirmed in the presence and absence of mannose-6-phosphate or one of the methods described. 26. The expression vector or recombinant nucleotide expression vector encodes a signal peptide. The method according to any one of paragraphs 8 to 15 and 21 to 25, or any one of claims 8 to 15, The method according to any one of paragraphs 16 to 17, when the method is directly or indirectly dependent on one of the methods. 27. A method of treating a human subject diagnosed with Mucopolysaccharidosis Type I (MPS I), comprising: A therapeutically effective amount of a recombinant nucleotide sequence encoding human IDUA is administered to the cerebrospinal fluid of the brain of the human subject. administering the current vector, thereby producing an IDUA vector that contains α2,6-sialylated glycans; wherein a depot is formed that releases wherein the recombinant vector, when used to transduce human neural cells in culture, The method further comprises producing said IDUA comprising said α2,6-sialylated glycans in a cell culture. 28. A method of treating a human subject diagnosed with Mucopolysaccharidosis Type I (MPS I), comprising: A therapeutically effective amount of a recombinant nucleotide sequence encoding human IDUA is administered to the cerebrospinal fluid of the brain of the human subject. Administering the current vector, resulting in glycosylated I without detectable NeuGc. a depot is formed that releases the DUA, wherein the recombinant vector When used to transduce human neural cells in culture, The method produces IDUA that is soluble in 5-aminopropyl 1,5-dihydropyridine but does not contain detectable NeuGc. 29. A method of treating a human subject diagnosed with Mucopolysaccharidosis Type I (MPS I), comprising: A therapeutically effective amount of a recombinant nucleotide sequence encoding human IDUA is administered to the cerebrospinal fluid of the brain of the human subject. and administering the present vector, which results in a vaccine containing detectable NeuGc and / or α-Gal antigens. wherein a depot is formed that releases glycosylated IDUA that is not When the recombinant vector is used to transduce human neural cells in culture, the cell culture The IDUA is glycosylated in water but does not contain detectable NeuGc and / or α-Gal antigens. The method. 30. A method of treating a human subject diagnosed with Mucopolysaccharidosis Type I (MPS I), comprising: A therapeutically effective amount of a recombinant nucleotide sequence encoding human IDUA is administered to the cerebrospinal fluid of the brain of the human subject. and administering the vector, which results in the release of the IDUA containing tyrosine sulfation. wherein a pore is formed, wherein the recombinant vector, when used to transduce human neural cells in culture, The method of producing said tyrosine-sulfated IDUA in cell culture. 31. Prior to or concurrently with the treatment with said human IDUA, (a) tacrolimus and mycophenone (b) rapamycin and mycophenolic acid; or (c) tacrolimus, rapamycin. , and corticosteroids, such as prednisolone and / or methylprednisolone. administering to said subject a combination of 31. The method of any one of paragraphs 27 to 30, further comprising: 32. The method of paragraph 31, wherein the immunosuppressive treatment is discontinued after 180 days. 33. The method of any one of paragraphs 1 to 32, wherein the human subject is under 3 years of age. 34. The human subject is under 3 years of age, and the expression vector or the recombinant nucleotide expression vector is administered. Vector is 1×10 10 GC / g brain mass or 5×10 10 Dose of GC / g brain mass (e.g., a single fixed dose (e.g., IC administration (e.g., by suboccipital injection)); see paragraphs 8-15 and 21- 33 or any one of claims 8 to 15, The method according to any one of paragraphs 16 to 20 in a dependent case. 35. The human subject is under 3 years of age, and the expression vector or the recombinant nucleotide expression vector is administered. Vector is 1×10 10 GC / g brain mass ~5×10 10 A range of doses of GC / g brain mass (e.g., a single constant (e.g., IC administration (e.g., by suboccipital injection)); 21 to 33, or any one of claims 8 to 15, directly or indirectly. 21. The method according to any one of paragraphs 16 to 20, when the method is practically dependent on the [Brief description of the drawings]

[0024] (4. BRIEF DESCRIPTION OF THE DRAWINGS) [Figure 1] Amino acid sequence of human IDUA. Six N-linked glycosylation sites (N) are bolded and underlined; one tyrosine-O-sulfation site (Y) is bolded and underlined. The complete sulfation site sequence is [ka] are shaded; and disulfide bonds (two cysteine ​​residues; C) are in bold and The N-terminus of the secreted recombinant product produced in CHO cells is A 26 However, humans The N-terminus of the native intracellular enzyme in liver is E 27 (Kakkis et al., 1994, Prot Exp Puri f 5: 225-232, p. 230).

[0025] [Diagram 2]Multiple sequence alignment with known orthologues of hIDUA. Sequences were aligned using Clustal X ver.2 (Larkin MA et al., 2007, "Clustal W and Clustal X version 2.0," Bioinformatics 23(21):2947-2948). Species names and protein IDs are as follows: human (Homo sapiens; NP_000194.2), dog (Canis familiaris; M81893.1), cow (Bos taurus; XP_002688492.1), mouse (Mus musculus; NP_032351.2), rat (Rattus norvegicus; NP_001165555.1), platypus (Ornithorhynchus anatinus; XP_001514102.2), chicken (Gallus gallus; XP_001514102.2), and reptile (Pterygota spp.; XP_001514102.2). gallus; NP_001026604.1), African clawed frog (Xenopus laevis; NP_001087031.1), zebrafish (Danio rerio; XP_001923689.3), sea urchin (Strongylocentrotus purpuratus; XP_796813.3), Ciona intestinalis (Ciona intestinalis; XP_002120937.1), and fruit fly (Drosophila melanogaster; NP_609489.1).N-glycosylation sites of the human protein (N110, N190, N336, N372, T374, N415, N451); residues involved in substrate binding (R89, H91, N181, E182, H262, K264, E299, D349, and R363) and in interactions with the N-glycan at N372 (P54, H58, W306, S307, Y355, R368, and Q370) are indicated by shading (Maita et al., 2013, PNAS 110: 14628-14633; modified from supplementary material, Fig. S8).

[0026] [Diagram 3] MPS I mutations, IDUA structural changes and phenotypes. (From Saito et al., Mol Genet Metab 111:107-112, Table 1).

[0027] [Figure 4] Oligosaccharides of the six glycosylation sites of recombinant human OL-iduronidase secreted by CHO cells. C (complex); M, high mannose; P, phosphorylated high mannose. Capital letters denote well-identified, major oligosaccharides, whereas lower case letters denote minor or poorly characterized components. (From Zhao et al., 1997, J Biol Chem 272:22758-22765).

[0028] [Diagram 5] Clustal multiple sequence alignment of AAV capsids 1-9 (SEQ ID NOs: 16-26). Amino acid substitutions (shown in bold on the bottom row) can be added to AAV9 and AAV8 capsids by "recruiting" amino acid residues from corresponding positions in other aligned AAV capsids. "HVR" = sequence regions called hypervariable regions. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0029] 5. Detailed Description of the Invention The present invention includes patients diagnosed with Hurler, Hurler-Scheie or Scheie syndromes. The cerebrospinal fluid (CSF) of the central nervous system of a human subject diagnosed with Mucopolysaccharidosis type I (MPS I), including, but not limited to, Delivery of fully human glycosylated (HuGly) α-L-iduronidase (HuGlyIDUA) to cerebrospinal fluid (CSF) In a preferred embodiment, treatment is via gene therapy - for example, human IDUA (hIDUA). Viral vectors or other DNA expression constructs encoding hIDUA or derivatives of hIDUA. The drug was administered to the CSF of patients (human subjects) diagnosed with MPS I, resulting in continuous complete human glial proliferation. To generate a persistent depot of transduced cells that delivers cosylated transgene products to the CNS. This is achieved by: HuGlyIDUA is secreted from the depot into the CSF and is secreted by cells in the CNS. The enzyme is then endocytosed and "cross-corrects" the enzyme defect in the recipient cell. In one embodiment, HuGlyIDUA is produced in cell culture and used as an enzyme replacement therapy ("ERT") in For example, the enzyme can be administered by injection. Proaches offer several advantages over ERT – the enzyme can cross the blood-brain barrier and The CNS is not treated by systemic delivery of the enzyme; Unlike conventional approaches, direct delivery of enzymes to the CNS not only poses significant costs but also increases the risk of infection. Repeated injections would be necessary, which would create risk.

[0030] The HuGlyIDUA encoded by the transgene may be selected from the group consisting of, but not limited to, SEQ ID NO: 1, human IDUA (hIDUA) having the amino acid sequence of For example, but not limited to, the orthologue of IDUA shown in FIG. The present invention may include derivatives of hIDUA that contain amino acid substitutions selected from non-conserved residues corresponding to Such mutations are shown in FIG. 3 (Sa Ito et al., 2014, Mol Genet Metab 111:107-112, Table 1 listing 57 MPS I mutations or Venturi et al., each of which is incorporated herein by reference in its entirety. 2002, Human Mutation #522 Online ("Venturi 2002"), or Bertola et al., 201 1, severe, moderate, as reported by Human Mutation 32:E2189-E2210 ("Bertola 2011"); Any mutations identified in more severe, moderate, or attenuated MPS I phenotypes (Provided that it does not include

[0031] For example, amino acid substitutions at specific positions in hIDUA are shown in FIG. 2, which is incorporated herein by reference in its entirety. The ortholog reported in Maita et al. (2013, PNAS 110:14628, Figure S8) The corresponding sequence found at that position in the IDUA orthologue shown in The amino acids may be selected from the non-conservative amino acids shown in FIG. or any of the deleterious mutations reported in Venturi 2002 or Bertola 2011, supra. The resulting transgene product may be used in cell culture or We performed in vitro studies to ensure that the mutations did not impair IDUA function in test animals. The preferred amino acid substitutions, deletions, etc. can be tested using the assays described below. or addition, conventional in vitro assays for MPS I in cell culture or animal models. maintain or increase the enzyme activity, stability, or half-life of IDUA as tested by For example, the enzymatic activity of the introduced gene product should be such that it can be expressed as 4-methyl-2-propanediol as a substrate. can be assessed using a conventional enzyme assay with umbelliferyl α-L-iduronide. (For exemplary IDUA enzyme assays that can be used, see, e.g., each of them in its entirety. Hopwood et al., 1979, Clin Chim Acta 92:257-260, which is incorporated herein by reference. 265; Clements et al., 1985, Eur J Biochem 152: 21-28; and Kakkis et al., 1994, (See Prot Exp Purif 5:225-232). The ability of the transgene product to correct the MPS I phenotype. For example, by transfecting MPS I cells in culture with a viral vector or vectors encoding hIDUA or derivatives. By transducing other DNA expression constructs; rHuGlyIDUA into MPS I cells in culture or a derivative; or by inducing MPS I cells to express rHuGlyIDUA or a derivative and Determine correction of the defect in MPS I cultured cells by co-culturing with human host cells engineered to secrete For example, by measuring IDUA enzyme activity and / or GAG storage in MPS I cells in culture can be assessed in cell culture by detecting a decrease in Myerowitz and Neufeld, 1981, J Biol. Chem 256: 3044-3048; and Anson et al., 1992, Hum Gene Ther 3: 371-379. I want to.

[0032] Animal models for MPS I include mice (see, e.g., Clarke et al., 1997; Hum Mol Genet. 6(4):503-511), hybrid domestic cats (see, e.g., Haskins et al., 1979, Pediatrics 1999, 101:111-112, and tr Res 13(11):1294-97), and some breeds of dogs (see, e.g., Menon et al. 1992, Genomics 14(3):763-768; Shull et al., 1982, Am J Pathol 109(2):244- A canine MPS I model has been described (see references in refs. 248). Hurler syndrome, the most severe form of MPS I, is characterized by a loss of detectable protein. The high gene homology between the IDUA proteins (see the alignment in Figure 2) (see references below) means that hIDUA is functional in animals and that therapeutics involving hIDUA can be tested in these animal models.

[0033] Preferably, the rHuGlyIDUA transgene functions in neuronal and / or glial cells. Expression control elements such as the CB7 promoter (chicken β-actin promoter and and CMV enhancer) and is driven by the vector. Other expression control elements that enhance expression of the transgene (e.g., chicken β-actin inserts) The huIDUA transgene can contain the ribosomal DNA and rabbit β-globin polyA signal. The cDNA constructs for this purpose were designed to ensure proper co- and post-translational expression by transduced CNS cells. Covalently binds to a signal peptide to ensure its processing (glycosylation and protein sulfation). The gene sequence should include a signal peptide used by CNS cells. for: Oligodendrocyte-Myelin Glycoprotein (hOMG) Signal Peptide: [ka] Cellular repressor of E1A stimulated genes 2 (hCREG2) signal peptide: [ka] V-set and transmembrane domain-containing 2B (hVSTM2B) signal peptide: [ka] Protocadherin alpha-1 (hPCADHA1) signal peptide: [ka] ·FAM19A1(TAFA1) signal peptide: [ka] Interleukin-2 signal peptide: [ka] These are possible, but not limited to these. A signal peptide is also referred to herein as a leader sequence or leader peptide. This can be done.

[0034] The recombinant vectors used to deliver the transgenes are expressed in neurons and / or glia. The target cell should have tropism for cells of the CNS, including but not limited to cells. Suitable vectors can include non-replicating recombinant adeno-associated viral vectors ("rAAV"), particularly Preferred are viral vectors having an AAV9 or AAVrh10 capsid in the vector. No. 7,906,111, incorporated herein by reference. Capsids having AAV / hu.31 and AAV / hu.32 are particularly preferred, but are not limited to these. AAV variant capsids that are not included in the present specification; No. 8,628,966, U.S. Pat. No. 8,927,514, and Smith et al., 2014, M AAV variant capsids described by Chatterjee in ol Ther 22:1625-1634 However, "naked DNA" constructs (see Section 5.2) can be used. The vectors are called lentiviral vectors, vaccinia virus vectors, or non-vaccinia virus vectors. using other viral vectors, including but not limited to viral expression vectors It is possible.

[0035] Pharmaceutical compositions suitable for administration to the CSF include a physiologically compatible aqueous buffer, a surfactant, and The formulation comprises a suspension of the rHuGlyIDUA vector in a formulation buffer containing optional excipients. In one embodiment, the pharmaceutical composition is suitable for intracisternal administration (injection into the cisterna magna). In one embodiment, the pharmaceutical composition is suitable for injection into the subarachnoid space via a C1-2 puncture. In some embodiments, the pharmaceutical composition is suitable for intrathecal administration. In some embodiments, the pharmaceutical composition is administered intraventricularly via lumbar puncture. It is suitable for administration to

[0036] A therapeutically effective dose of the recombinant vector can be administered via intrathecal administration (i.e., intrathecal injection). The recombinant vector is then injected into the CSF to transduce cells of the CNS. This can be achieved in several ways, e.g., intracranially (to This can be achieved by injection into the ventricles (cisterna magna or ventricles), or into the lumbar cisterna. Intracisternal (IC) injection can be performed via CT-guided suboccipital puncture; Injection into the subarachnoid space via C1-2 puncture should be performed if feasible for the patient. or a lumbar puncture (a diagnostic procedure typically performed to collect a sample of CSF) It can be used to access the CSF. Alternatively, it can be administered intracerebroventricularly (ICV) (blood-brain using a technique that does not penetrate the hilum, a more invasive technique used for the delivery of anti-infective or anti-cancer drugs. Alternatively, the recombinant vector can be administered intranasally. may be used to deliver recombinant vectors to the CNS. C of at least 9.25 μg / mL min Use a dose that maintains the patient at a constant concentration or a concentration in the range of 9.25 to 277 μg / mL. It should be used.

[0037] CSF concentrations were determined by directly measuring the concentration of rHuGlyIDUA in CSF fluid obtained via occipital or lumbar puncture. The concentration of rHuGlyIDUA detected in the patient's serum was monitored by In one embodiment, the serum rHuGlyIDUA concentration is 10 A range of ng / mL to 100 ng / mL indicates that the amount of rHuGlyIDUA in the CSF is 1 to 30 mg. In one embodiment, the recombinant vector maintains rHuGlyIDUA in serum at 10 ng / mL to 100 ng / mL. Administer into the CSF in a dose that will sustain the desired therapeutic effect.

[0038] By way of background, human IDUA is translated as a polypeptide of 653 amino acids, which is depicted in FIG. It is N-glycosylated at six potential sites (N110, N190, N336, N372, N415, and N451). The signal sequence is removed and the polypeptide is processed to its mature form in the lysosome. The 75 kDa intracellular precursor is trimmed to 72 kDa within a few hours, and finally, after 4–5 days The secreted form of IDUA (depending on the assay used) is then processed to a 66 kDa intracellular form. Depending on the size of the protein, either 76 kDa or 82 kDa, is readily endocytosed into cells via the mannose-6-phosphate receptor. are transformed into smaller intracellular forms and processed in the same manner (each of which is Myerowitz and Neufeld, 1981, J Biol C, incorporated herein by reference. hem 256: 3044-3048; Clements et al., 1989, Biochem J. 259: 199-208; Taylor et al. 1991, Biochem J. 274: 263-268; and Zhao et al., 1997, J Biol Chem 272:2275. (See 8-22765).

[0039] The overall structure of hIDUA consists of three domains: residues 42-396 contain a classical (β / α) triad The TIM barrel domain is formed by the thiol phosphate isomerase (TIM) enzyme; residues 27-42 and 397-545 form the short forming a β-sandwich domain having a helix-loop-helix (482-508); and Residues 546-642 form an Ig-like domain. The last two domains are 541 and C 577 The β-sandwich and Ig-like domains are linked by disulfide bridges between the TIM It is bound to the first, seventh, and eighth α-helices of the barrel. 3) is inserted between the eighth β-strand and the eighth α-helix of the TIM barrel, N-glycosylated N is required for substrate binding and enzyme activity 372 (See Figure 1 and each of its entirety.) Maita et al., 2013, PNAS 110: 14628-146, the contents of which are incorporated herein by reference. See the crystal structure in Saito et al., 2014 Mol Genet Metab 111:107-112. sea ​​bream).

[0040] The present invention is based in part on the following principles: (i) Neurons and glial cells of the CNS undergo glycosylation and endothelial cell death, which are active processes in the CNS. Contains the cellular machinery for post-translational processing of secreted proteins, including tyrosine-O-sulfation The post-translational modifications carried out by human CNS cells are described in their entirety in the following references. For example, the human brain mannose-6-phosphate (M6P) glycoproteome It has been described that the brain contains many more individual isoforms than are found in other tissues. It was noted that the chromosomes contained more proteins than the chromosomes containing mannose-6-phosphorylated proteins. , Sleat et al., 2005, Proteomics 5: 1520-1532 and Sleat, 1996, J Biol Chem 271:19191-98; and the production of secreted tyrosine sulfated glycoproteins by neuronal cells. The literature reporting this is based on Kanan et al., 2009, Exp. Eye Res. 89: 559-567 and Kanan and Al-Ubai See di, 2015 Exp. Eye Res. 133: 126-131. (ii) hIDUA has six asparagine ("N") glycosylation sites, identified in FIG. 1 ( N 110 FT;N 190 V.S.; N 336 T.T.; N 372 NT; N 415 H.T.; N 451 RS). N 372 N-glycosylation of Mannose-6-phosphorylation is required for binding and enzymatic activity, and is involved in cellular uptake of the secreted enzyme. N-linked glycosylation sites are required for the translocation and cross-revision of MPS I cells. Although it contains mannose and phosphorylated mannose carbohydrate moieties (Fig. 4), only the secreted form is taken up by cells. (Myerowitz and Neufeld, supra, 1981). The roach was measured by polyacrylamide gel electrophoresis (depending on the assay used). 2,6-sialylated and mannose-6 phosphorylated IDUA glycoprotein of 76-82 kDa The secreted glycosylated / phosphorylated IDUA is a morphogenetic protein of the CNS. It is taken up and correctly processed by non-transduced neurons and glial cells. should be done. (iii) Cellular and intracellular trafficking / uptake of lysosomal proteins is mediated by M6P. Daniel As was done for the iduronate-2-sulfatase enzyme in the literature by E., 2002, It is possible to measure the M6P content of secreted proteins. In the presence of IL-1, non-neuronal or non-glial cells, such as the genetically engineered cells of Daniele, 2002, The uptake of zymogens produced by transplanted kidney cells was shown by Daniele, 2002. As previously reported, the presence of inhibitory M6P is predicted to reduce the expression of M6P to levels close to those of control cells. Even under low oxidative stress, the enzyme precursors produced by brain cells, e.g., neurons and glial cells, Uptake was 4-fold higher than in control cells, and in the absence of the inhibitory M6P, equivalent levels of enzyme activity (i.e., uptake) of zymogens produced by renal cells This is expected to remain at a high level, as shown by Daniele et al. (2002). The assay can be used to predict the M6P content of the enzyme precursor produced by brain cells, specifically It is possible to compare the M6P content in the enzyme precursors produced by different cell types. The gene therapy approach described herein suppresses M6 expression in such assays. In the presence of P, high levels of hIDUA were secreted continuously, which could be taken up by neurons and glial cells. It should bring about. (iv) In addition to the N-linked glycosylation sites, hIDUA has N-glycosylation sites required for binding and activity. 3 72 A tyrosine ("Y") sulfation site near the domain containing [ka] (See, e.g., Protein Tyrosine Sulfation, Analysis of the amino acids surrounding the tyrosine residues that are affected by the tyrosine residues in Yang et al., 2015, Molecular Biology. les 20:2138-2164, especially p. 2154. The "Rules" can be summarized as follows: The Y residue has E or D within the +5 to -5 positions from Y, and the -1 position of Y is neutral or acidic. - a neutral charged amino acid, but not a basic amino acid, such as R, K, or H, that disables sulfation Without intending to be bound by any theory, tyrosine sulfated regions Mutations in the IL-1 gene (e.g., W306L) are known to be associated with reduced enzyme activity and disease. Therefore, sulfation of this site in hIDUA may be crucial for activity (Maita et al., 2013). , PNAS 110:14628, pp. 14632-14633). (v) glycosylation of hIDUA by human cells of the CNS to improve stability, half-life, and Glycans are added that can reduce unwanted aggregation of the transgene product. In addition, the glycan added to the HuGlyIDUA of the present invention contains 2,6-sialic acid, Neu5Ac ("NANA"). However, its hydroxylated derivative NeuGc (N-glycolylneuraminic acid, i.e. " Highly processed complex-type biantennary N-glycans that do not incorporate NGNA or Neu5Gc Such glycans contain the 2,6-sialyltransferases required for this post-translational modification. It does not have a transesterase and does not produce bisecting GlcNAc, but it does produce a substitute for Neu5Ac (NANA). In particular, the atypical (and potentially immunogenic) sialic acid Neu5Gc(NGNA) is It is not present in the laronidase produced in additional CHO cells. For example, Dumont et al. Literature, 2016, Critical Rev in Biotech 36(6):1110-1122 (Early online pp. 1-13, p. 5 and Hague et al., 1998, Electrophor 19:2612-2630 ("CHO cell lines are capable of expressing α2,6-sialylated is "phenotypically restricted" with respect to glycosylation due to the lack of glycosylation enzymes In addition, CHO cells react with anti-α-Gal antibodies present in most individuals. They also produce the immunogenic glycan, α-Gal antigen, which can induce anaphylaxis at high concentrations. See, e.g., Bosques, 2010, Nat Biotech 28: 1153-1156. The human glycosylation pattern of HuGlyIDUA reduces the immunogenicity of the transgene product, and Efficacy should be improved. (vi) Tyrosine sulfation of hIDUA, an active post-translational process in human CNS cells, enhances the expression of transgenes. The processing and activity of lysosomal proteins should be improved. The significance of oxidation remains unclear; however, tyrosine sulfation has been shown to be involved in other proteins. This increases the affinity of protein-protein interactions (antibodies and receptors) and enhances the affinity of proteins. It has been shown that proteolytic processing of peptide hormones is enhanced (Moore, 2002). 2003, J Biol. Chem. 278:24243-46; and Bundegaard et al., 1995, EMBO J 14: 3073-7. 9). Tyrosine sulfation, which occurs as the final step in the processing of IDUA, Tyrosine protein sulfotransferase 1 (TPST1), which is responsible for the Gene expression data for PST1 can be accessed at, for example, http: / / www.ebi.ac.uk / gxa / home. (which can be found in the EMBL-EBI Expression Atlas available at http: / / www.embl.org / expressionatlas.html) Such post-translational modifications are at best expressed in the CHO cell product Laronida. Unlike human CNS cells, CHO cells are not secretory cells and They have limited post-translational tyrosine sulfation capacity (see, e.g., Mikkelsen and Ezban, 1991, Biochemistry 30: 1533-1537, especially the discussion on page 1537). (vii) The immunogenicity of the transgene product depends on the immune status of the patient, the structure of the injected protein drug, The efficacy and safety of the treatment may be influenced by a variety of factors, including the dosage and characteristics, route of administration, and duration of treatment. Process-related impurities, such as host cell proteins (HCPs), host cell DNA, and chemical residues, as well as and product-related impurities, e.g., protein degradation products and structural characteristics, e.g., glycosylation, acid The aggregation and agglutination (subvisible particles) of the antibody can act as an adjuvant to enhance the immune response. The amount of process-related and product-related impurities may increase immunogenicity. Manufacturing processes: cell culture, purification, formulation that may affect commercially manufactured IDUA products In gene therapy, proteins are produced in vivo. As a result, there are no process-related impurities and the protein product is produced by recombinant technology. Product-related impurities / degradants associated with the protein produced, e.g., protein aggregates and Protein oxidation is unlikely. Aggregation is associated with, for example, protein production and storage. These include high protein concentrations, surface interactions with manufacturing equipment and vessels, and specific buffer solutions. However, the in vivo expression of the transgene is not consistent with the purification process using the system. In the case of β-lactamase, these conditions that promote aggregation are not present. Oxidation of heptaphan and histidine is associated with protein production and storage, e.g. Stressed cell culture conditions, exposure to metals and air, and in buffers and excipients Proteins expressed in vivo are stressed and However, humans, like most organisms, are equipped with an antioxidant defense system. thereby not only reducing oxidative stress but also repairing and / or reversing oxidation. Therefore, it is unlikely that proteins produced in vivo are in an oxidized form. Both aggregation and oxidation can affect efficacy, PK (clearance), and raise immunogenic concerns. The gene therapy approaches described herein can be used to increase the yield of genomic DNA compared to commercially manufactured products. The antibody should continually secrete hIDUA, which has reduced immunogenicity compared to the antibody.

[0041] For the reasons mentioned above, production of HuGlyIDUA is not associated with, for example, MPS I disease (Hurler, Hurler-Schmidt, C of a patient (human subject) diagnosed with glaucoma or glaucoma (including, but not limited to, glaucoma or glaucoma) SFs were administered a viral vector or other DNA expression construct encoding HuGlyIDUA. , fully human glycosylated, mannose-6-phosphate dehydrogenase secreted by transduced CNS cells By creating a durable depot in the CNS that provides a constant supply of oxidized and sulfated transgene products, - To provide a "bio-better" molecule for the treatment of MPS I achieved by gene therapy The HuGlyIDUA transgene product secreted from the depot into the CSF should be The enzyme is then endocytosed by the vesicles and “cross-corrected” the enzyme defect in MPS I recipient cells. It brings about "positive"

[0042] All hIDUA molecules produced in gene or protein therapy approaches are complete. It is not essential that the entire glycoprotein be glycosylated and sulfated. The quality population was designed to have sufficient glycosylation (2,6-sialylation and mannose) to demonstrate efficacy. The objective of the gene therapy procedure of the present invention is to The goal of the study was to slow or stop the progression of the disease. Efficacy was measured by improving cognitive function (e.g., cognitive function). prevention or reduction of cognitive decline; disease biomarkers in CSF and / or serum ( and / or increased CSF and / or serum IDUA enzyme activity. Monitoring for signs of inflammation and other safety events. It is also possible.

[0043] As an alternative or adjunct to gene therapy, the rHuGlyIDUA glycoprotein has been developed using recombinant DNA technology. The glycoprotein can be produced in human cell lines by recombinant DNA technology and delivered systemically and / or for ERT. Such recombinant glycoproteins can be administered to patients diagnosed with MPS I in the CSF for Human cell lines that can be used for protein production include, but are not limited to, a few examples: Some examples include HT-22, SK-N-MC, HCN-1A, HCN-2, NT2, SH-SY5y, hNSC11, ReNcell VM, and human embryonic stem cells. Human embryonic kidney 293 cells (HEK293), fibrosarcoma HT-1080, HKB-11, CAP, HuH-7, retinal cell line, PER.C6, or contains RPE (e.g., rHuGlyIDUA glycoprotein, which is incorporated by reference in its entirety). See Dumont et al. for a review of human cell lines that can be used for recombinant production of , 2016, Critical Rev in Biotech 36(6):1110-1122 "Human cell lines for biopharmaceutical manufacturing: Human cell lines for biopharmaceutical manufacturing: History, current status, and future prospects Complete glycosylation, especially sialic acid To ensure the addition and tyrosine sulfation, the cell line used for production was tyrosine-O-sulfated. α-2,6-sialyltransferase (or α-2,3- and α-2,6-sialyltransferase) The host cell may be engineered to co-express the TPST-1 and TPST-2 enzymes, as well as both the TPST-1 and TPST-2 enzymes. This can be strengthened by

[0044] While delivery of rHuGlyIDUA should minimize immune responses, The most obvious potential source of toxicity is a genetic deficiency of IDUA, and thus a loss of protein and / or Expression in human subjects that are potentially intolerant of the vectors used to deliver the transgene The main cause of death is the development of immunity against the immunized hIDUA protein.

[0045] Thus, in a preferred embodiment, co-treating a patient with immunosuppressive therapy - particularly in the setting of an ID - Suitable for treating patients with severe disease (e.g., Hurler) whose UA levels are close to 0 Tacrolimus or rapamycin (sirolimus) can be combined with, for example, mycophenolic acid. Combined and / or prednisolone and / or methylprednisolone regimens in combination with thyrosteroids or other immunosuppressants used in tissue transplant procedures. Immunosuppressive therapy involving immunosuppressive regimens may be utilized. The gene therapy regimen may be administered during the gene therapy course and, in some embodiments, prior to immunosuppressive therapy. Immunosuppressive therapy may be preferred at the discretion of the treating physician, as well as gene therapy treatment. If immune tolerance is then induced, e.g., after 180 days, It can be stopped.

[0046] In one embodiment, the immunosuppression is achieved by the administration of corticosteroids, such as prednisolone and / or administration of methylprednisolone and tacrolimus and / or tacrolimus administered optionally with MMF For example, a single corticosteroid, such as methylprednisolone, may be used. Donisolone was injected, followed by oral corticosteroids, and the treatment was graded over a 12-week period. At the same time, tacrolimus and sirolimus are administered in combination at low doses. (e.g., to maintain serum concentrations of 4-8 ng / mL) or alone at the label dose for 24-48 weeks. Tacrolimus or sirolimus can be administered orally in combination with MMF. Thus, patients can receive early doses of immediately available steroids. The steroids were then maintained orally and tapered over 12 weeks. Further immunosuppression is provided by tacrolimus and / or sirolimus, optionally in combination with MMF. This is maintained throughout the 48 weeks.

[0047] The combined delivery of HuGlyIDUA to the CSF with the delivery of other available therapeutic agents is useful in the methods of the invention. Additional therapeutic agents may be administered prior to, simultaneously with, or following the gene therapy treatment. Available Treatments for MPS I that can be Combined with the Gene Therapy of the Invention These include, but are not limited to, the use of laronidase administered systemically or into the CSF. and / or HSCT.

[0048] In one embodiment, there is provided a method of treating a human subject diagnosed with MPS I, comprising administering to said human The study involved administering a therapeutically effective amount of recombinant human IDUA produced by human neuronal cells to the cerebrospinal fluid of the subjects' brains. In one embodiment, the method comprises delivering MPS I to a subject. A method of treating a diagnosed human subject, comprising administering human glial cells to cerebrospinal fluid of the brain of the human subject. delivering a therapeutically effective amount of recombinant human IDUA produced by the cells. As described herein.

[0049] In one embodiment, the method of treating a human subject diagnosed with Mucopolysaccharidosis Type I (MPS I) comprises administering to the subject a administering to the cerebrospinal fluid of the brain of said human subject a therapeutically effective amount of α2,6 sialylated human α-L-iduronidase; and delivering to said subject prior to or concurrently with treatment with human IDUA. and administering the immunosuppressant treatment and continuing the immunosuppressant treatment thereafter. This document provides:

[0050] In one embodiment, there is provided a method of treating a human subject diagnosed with MPS I, comprising: A therapeutically effective amount of glycosylated human IDUA without detectable NeuGc in the cerebrospinal fluid of the brains of study subjects. and administering to said subject immunosuppression prior to or concurrently with treatment with human IDUA. The method described herein includes administering the treatment and continuing the immunosuppressive treatment thereafter. provide.

[0051] In one embodiment, there is provided a method of treating a human subject diagnosed with MPS I, comprising: A therapeutically effective amount of the compound containing no detectable NeuGc and / or α-Gal antigen in the cerebrospinal fluid of the brain of the subject. delivering glycosylated human IDUA; and prior to or concurrently with treatment with human IDUA. administering to the subject an immunosuppressive treatment and continuing the immunosuppressive treatment thereafter. is provided herein.

[0052] In one embodiment, there is provided a method of treating a human subject diagnosed with MPS I, comprising: delivering a therapeutically effective amount of human IDUA containing tyrosine-sulfation to the cerebrospinal fluid of the brain of a subject; and and administering to the subject an immunosuppressant treatment prior to or concurrently with the treatment with human IDUA, and then Such methods are provided herein, comprising continuing the immunosuppressive treatment even after the administration of the antibody.

[0053] In one embodiment, there is provided a method of treating a human subject diagnosed with MPS I, comprising: administering to the brain of a subject an expression vector encoding human IDUA, wherein said IDUA is human When expressed from the expression vector in immortalized neural cells, said administering; and

[0054] administering an immunosuppressive treatment to the subject prior to or simultaneously with administration of the expression vector; The methods provided herein include continuing the immunosuppressive treatment thereafter.

[0055] In one embodiment, there is provided a method of treating a human subject diagnosed with MPS I, comprising: administering to the brain of a subject an expression vector encoding human IDUA, wherein said IDUA is human When expressed from the expression vector in immortalized neural cells, said administration being free of exocytable NeuGc; and and simultaneously administering immunosuppressant treatment to the subject and continuing the immunosuppressant treatment thereafter. Said methods are provided herein.

[0056] In one embodiment, the method of treating a human subject diagnosed with MPS I comprises the steps of: a) administering to said human subject administering to the brain of a subject an expression vector encoding human IDUA, IDUA is glycosylated when expressed from the expression vector in human or immortalized neural cells. said administering said antibody to said patient, said antibody being immunized with said antibody against NeuGc and / or α-Gal antigens; and step b) administering the expression vector before and / or simultaneously therewith and / or after said administration. and administering to the subject an immunosuppressant treatment and continuing the immunosuppressant treatment thereafter. Provided in the specification.

[0057] In one embodiment, the method of treating a human subject diagnosed with MPS I comprises: administering to said human subject administering to the brain of a subject the expression vector encoding human IDUA, said IDUA being a human immortal The administered polypeptide is tyrosine sulfated when expressed from the expression vector in an activated neuron. and administering to said subject an immunosuppressive treatment prior to or concurrently with administration of the expression vector. and continuing the immunosuppressive treatment thereafter. do.

[0058] In one embodiment, the method of treating a human subject diagnosed with MPS I comprises: administering to said human subject A therapeutically effective amount of a recombinant nucleotide expression vector encoding human IDUA was administered to the cerebrospinal fluid of the brain of and administering to said patient a subject in need of treatment with an IDUA comprising an α2,6 sialylated glycan. said administering, wherein a depot is formed; and said administering is performed prior to or contemporaneously with administration of the expression vector. and occasionally administering immunosuppressive treatment to said subject, and continuing said immunosuppressive treatment thereafter. Such methods are provided herein.

[0059] In one embodiment, there is provided a method of treating a human subject diagnosed with MPS I, comprising: The recombinant nucleotide expression vector encoding human IDUA is administered to the cerebrospinal fluid of the brain of the subject in a therapeutically effective amount. and administering to the subject a glycosylated human IDU containing no detectable NeuGc. and, prior to administration of the expression vector, a depot is formed that releases A. At the same time, administering immunosuppressive treatment to the subject and continuing the immunosuppressive treatment thereafter. The method provided herein comprises:

[0060] In one embodiment, there is provided a method of treating a human subject diagnosed with MPS I, comprising: The recombinant nucleotide expression vector encoding human IDUA is administered to the cerebrospinal fluid of the brain of the subject in a therapeutically effective amount. and administering to the subject a subject a subject that does not contain detectable NeuGc and / or α-Gal antigens. a depot is formed that releases glycosylated human IDUA; and The subject is administered an immunosuppressive treatment prior to or concurrently with administration of the antibody. Such methods include continuing the regimen.

[0061] In one embodiment, there is provided a method of treating a human subject diagnosed with MPS I, comprising: The recombinant nucleotide expression vector encoding human IDUA is administered to the cerebrospinal fluid of the brain of the subject in a therapeutically effective amount. and administering to the depot a tyrosine sulfation-containing IDUA. wherein said administering results in the formation of a cellular endothelial cell line; and prior to or simultaneously with administration of the expression vector, administering to the subject an immunosuppressive treatment and continuing the immunosuppressive treatment thereafter. is provided herein.

[0062] In one embodiment, the production of said IDUA comprising α2,6 sialylated glycans is achieved by the cell culture Transducing a human neuronal cell line with said recombinant nucleotide expression vector in culture. In one embodiment, the glycosyl ester does not contain detectable NeuGc. The production of modified IDUA was carried out in human neuroblastoma using the recombinant nucleotide expression vector in cell culture. In one embodiment, detectable NeuGc and The production of said glycosylated IDUA free of the α-Gal antigen and / or α-Gal antigen is carried out in cell culture by subjecting said recombinant IDUA to Validation by transducing human neural cell lines with nucleotide expression vectors In one embodiment, the production of said IDUA comprising tyrosine sulfation is achieved by inducing said composition in cell culture. Validation by transducing human neuronal cell lines with recombinant nucleotide expression vectors In a specific embodiment, the IDUA transgene encodes a signal peptide. In some embodiments, the human neuronal cell line is selected from the group consisting of HT-22, SK-N-MC, HCN-1A, HCN-2, NT2, SH-S Y5y, hNSC11 or ReNcell VM.

[0063] In one embodiment, there is provided a method of treating a human subject diagnosed with MPS I, comprising: The recombinant nucleotide expression vector encoding human IDUA is administered to the cerebrospinal fluid of the brain of the subject in a therapeutically effective amount. and administering to said subject a subject a subject with a glycan-containing IDUA. and said administering includes administering an expression vector to said patient, said administering including administering a depot to said patient that delivers the expression vector to said patient; and administering immunosuppressant therapy to said subject at the same time, and continuing said immunosuppressant therapy thereafter. wherein the recombinant vector is used to transduce human neural cells in culture. resulting in production of said IDUA comprising said α2,6 sialylated glycan in said cell culture. In one embodiment, the human neuronal cells are -22, SK-N-MC, HCN-1A, HCN-2, NT2, SH-SY5y, hNSC11 or ReNcell VM cells.

[0064] In one embodiment, there is provided a method of treating a human subject diagnosed with MPS I, comprising: The recombinant nucleotide expression vector encoding human IDUA is administered to the cerebrospinal fluid of the brain of the subject in a therapeutically effective amount. and administering to the subject a glycosylated IDUA containing no detectable NeuGc. said administering forming a releasing depot; and prior to administration of the expression vector, or At the same time, administering immunosuppressive treatment to the subject and continuing the immunosuppressive treatment thereafter. wherein the recombinant vector is used to transduce human neural cells in culture. and, if present, the amount of glycosylated IDUA in the cell culture that does not contain detectable NeuGc is In one embodiment, the method includes the step of producing a human lysate. The transduced cells were HT-22, SK-N-MC, HCN-1A, HCN-2, NT2, SH-SY5y, hNSC11 or ReNcell VM cells. It is.

[0065] In one embodiment, there is provided a method of treating a human subject diagnosed with MPS I, comprising: Expression of a therapeutically effective amount of recombinant nucleotide encoding human IDUA in the cerebrospinal fluid of the brain of a rat subject and administering a vector that results in detectable NeuGc and / or α-Gal antigens. a depot is formed that releases unglycosylated IDUA; and The subject is administered an immunosuppressive treatment prior to or concurrently with administration of the antibody. and continuing the inhibitory treatment, wherein the recombinant vector is transformed into human neural cells in culture. When used to transduce a glycosylated but detectable amount of the glycosylated protein in the cell culture, The method described herein results in the production of said IDUA free of NeuGc and / or α-Gal antigens. In one embodiment, the human neuronal cells are selected from the group consisting of HT-22, SK-N-MC, HCN-1A, HC N-2, NT2, SH-SY5y, hNSC11 or ReNcell VM cells.

[0066] In one embodiment, there is provided a method of treating a human subject diagnosed with MPS I, comprising: The recombinant nucleotide expression vector encoding human IDUA is administered to the cerebrospinal fluid of the brain of the subject in a therapeutically effective amount. and administering to the depot a tyrosine sulfation-containing IDUA. and administering to the subject an immunosuppressive treatment and continuing the immunosuppressive treatment thereafter; When the recombinant vector is used to transduce human neural cells in culture, the cells The method for producing the tyrosine sulfated IDUA in cell culture is described herein. In one embodiment, the human neuronal cells are selected from the group consisting of HT-22, SK-N-MC, HCN-1A, HCN-2 , NT2, SH-SY5y, hNSC11 or ReNcell VM cells.

[0067] In one embodiment, the human IDUA comprises the amino acid sequence of SEQ ID NO:1. In the method, immunosuppressive treatment is administered to the subject prior to or simultaneously with treatment with human IDUA (a (b) a combination of rapamycin and mycophenolic acid; In one embodiment, the immunosuppressant is administered to the patient, and the administration continues thereafter. Treatment will be discontinued after 180 days.

[0068] In a preferred embodiment, the glycosylated IDUA contains detectable NeuGc and / or α-Gal. As used herein, the phrase "detectable NeuGc and / or α-Gal" refers to NeuGc and / or α-Gal. and / or the α-Gal moiety is detectable by standard assay methods known in the art. For example, NeuGc means that the nucleotide sequence of ... Hara et al., 1989, "Reversed-Phase Liquid Chromatography with Fluorescence Detection," incorporated herein by reference. -induced N-acetylglucosamine and N-glycolylglucosamine dehydrogenase in human serum and urine, and in rat serum Highly Sensitive Determination of N-Acetyl- and N-Glycolylneuram inic Acids in Human Serum and Urine and Rat Serum by Reversed-Phase Liquid Chrom J. Chromatogr., B: Biomed. 377: 111-119 Alternatively, NeuGc can be detected by mass spectrometry. α-Gal can be detected using ELISA (see, e.g., Galili et al., 1998, "Monoclovir ELISA"). A sensitive method for measuring cell surface expression of α-Gal epitopes using monoclonal anti-Gal antibodies A sensitive assay for measuring alpha-Gal epitope expression on cells (by a monoclonal anti-Gal antibody.) Transplantation. 65(8):1129-32. ), or by mass spectrometry (see, for example, Ayoub et al., 2013, “Intact, Middle-A Combination of top-, middle-down, and bottom-up ESI and MALDI mass spectrometry techniques for separation Correct primary structure assessment and comprehensive glycoprofiling of tuximab mary structure assessment and extensive glyco-profiling of cetuximab by a combin ation of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectro (see, "Landes Bioscience. 5(5): 699-710") In addition, in the article by Platts-Mills et al., 2015, "Anaphylaxis to the sugar side chain α-gal Anaphylaxis to the Carbohydrate Side-Chain Alpha-gal” Immunol Allergy Cl See also the references cited in North Am. 35(2): 247-260.

[0069] 5.1 N-Glycosylation and Tyrosine Sulfation 5.1.1. N-Glycosylation Neurons and glial cells of the CNS express secreted proteins that contain glycosylation and tyrosine-O-sulfation. hIDUA is a secretory cell that possesses the cellular machinery for post-translational processing of proteins. Six asparagine ("N") glycosylation sites (N 110 FT;N 190 V.S.; N 336 T.T.; N 372 NT; N 415 H.T.; N 451 RS). 372 N-glycosylation of β-lactams affects substrate binding and enzyme activity. Mannose-6-phosphorylation is required for cellular uptake of the secreted enzyme and for the translocation of MPS I cells. N-linked glycosylation sites are complex, high mannose and phosphorylated. Although it contains a mannose carbohydrate moiety (Fig. 4), only the secreted form is taken up by cells. In the gene therapy approach described herein, 2,6 sialylated and mannose-6 lysine The phosphorylated IDUA glycoprotein should be secreted continuously. / Phosphorylated IDUA is taken up by untransduced neurons and glial cells of the CNS should be correctly processed.

[0070] Glycosylation of hIDUA by human cells of the CNS increases its stability, half-life, and allows for Importantly, glycans are added that can reduce unwanted aggregation of the transgene product. The glycan added to the HuGlyIDUA of the present invention contains 2,6-sialic acid and does not contain Neu5Ac ("NANA"). Incorporating its hydroxylated derivative NeuGc (N-glycolylneuraminic acid, or “NG Highly processed complex-type biantennary N-glycans that do not incorporate NA or Neu5Gc Such glycans are the 2,6-sialyltransferases required for this post-translational modification. It does not have spherase and does not produce bisecting GlcNAc, but it acts as a substitute for Neu5Ac (NANA). with Neu5Gc (NGNA), a sialic acid that is atypical for humans (and potentially immunogenic). It is absent in laronidase produced in CHO cells that are supplemented with It reacts with anti-α-Gal antibodies present in most individuals and induces anaphylaxis at high concentrations. The immunogenic glycan, α-Gal antigen, can be produced by the antibody. See, e.g., Bosques, 2010, Nat B See iotech 28: 1153-1156. Human glycosylation pattern of HuGlyIDUA of the present invention should reduce the immunogenicity and improve the efficacy of the transgene product.

[0071] All molecules produced in gene or protein therapy approaches are fully genetically engineered. It is not essential that the glycosylated and sulfated proteins are glycosylated and sulfated. Rather, the resulting glycoprotein assembly The group should undergo sufficient glycosylation and sulfation to demonstrate efficacy.

[0072] In certain embodiments, the HuGlyIDUA used in accordance with the methods described herein is When expressed in vivo or in vitro in mammalian or glial cells, the N-glycosylation 100% of the sylation sites may be glycosylated. However, those skilled in the art will recognize that glycosylation For the benefits of glycosylation to be achieved, not all N-glycosylation sites of HuGlyIDUA are N-glycosylation sites. It will be appreciated that glycosylation is not required. Rather, the benefits of glycosylation include the absence of N-glycosylation. Only a certain percentage of the glycosylation sites are glycosylated and / or expressed IDUA molecules This can be achieved if only a certain percentage is glycosylated. In the present invention, HuGlyIDUA used in accordance with the methods described herein is capable of inhibiting the expression of neuronal or glial cells. When expressed in vivo in cells or in vitro, the available N-glycosylation sites 10%~20%, 20%~30%, 30%~40%, 40%~50%, 50%~60%, 60%~70%, 70%~80%, 80%~9 In one embodiment, the glycosylated IgG is 0%, or 90% to 100% glycosylated. When expressed in vivo or in vitro in cells, according to the methods described herein 10%-20%, 20%-30%, 30%-40%, 40%-50%, 50%-60%, 60%- 70%, 70%-80%, 80%-90% or 90%-100% of the available N-glycosylation sites At least one is glycosylated.

[0073] In a specific embodiment, HuGlyIDUA is administered in vivo or in vivo in neuronal or glial cells. When expressed in vitro, HuGlyIDUA was used according to the methods described herein. At least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80% of the N-glycosylation sites present , 85%, 90%, 95% or 99% of the Asn residues (or other related residues) present at the N-glycosylation site ) at the N-glycosylation site of the resulting HuGlyIDUA. At least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or 99% are glycosylated.

[0074] In another specific embodiment, HuGlyIDUA is expressed in vivo in neuronal or glial cells. HuGlyIDU used in accordance with the methods described herein when expressed in vivo or in vitro. At least 10%, 20%, 30%, 40%, 50%, 60%, 70%, or 7% of the N-glycosylation sites present in the A molecule 5%, 80%, 85%, 90%, 95%, or 99% of the Asn residues present at N-glycosylation sites (or other glycosylated with the same linked glycan attached to the corresponding glycan residues (i.e., That is, at least 50%, 60%, 70%, 75%, or 80% of the N-glycosylation sites of the resulting HuGlyIDUA %, 80%, 85%, 90%, 95%, or 99% have identical attached glycans.

[0075] Importantly, the IDUA protein used in accordance with the methods described herein is capable of expressing a neuronal or When expressed in glial cells, prokaryotic host cells (e.g., E. coli) or This avoids the need for in vitro production in eukaryotic host cells (e.g., CHO cells). Alternatively, the results of the methods described herein (e.g., the use of neuronal or The N-glycosylation site of the IDUA protein is advantageously associated with the development of therapeutic agents in humans. CHO cells or E. coli cells produce proteins that are decorated with therapeutically relevant and beneficial glycans. When used for production, such advantages are not accessible; for example, CHO cells ( 1) does not express 2,6 sialyltransferase and therefore does not express 2,6 sialyltransferase during N-glycosylation. (2) cannot add sialic acid, and (3) adds Neu5Gc instead of Neu5Ac as the sialic acid. and E. coli does not naturally contain the components necessary for N-glycosylation. Therefore, in one embodiment, in neuronal or glial cells, The IDUA protein is expressed to produce HuGlyIDUA for use in the therapeutic methods described herein. The protein is N-glycosylated in human neuronal or glial cells. It is glycosylated, but not in the manner in which proteins are glycosylated in CHO cells. In another embodiment, the protein is expressed in a neuronal or glial cell. The IDUA protein from which HuGlyIDUA is derived and used in the therapeutic methods described herein is Glycosylated in the manner in which proteins are N-glycosylated in mammalian cells or glial cells. Such glycosylation can be carried out using prokaryotic host cells, e.g., E. coli. In some cases this is not possible without some effort.

[0076] Assays for determining the glycosylation pattern of a protein are known in the art. For example, hydrazinolysis can be used to analyze glycans. First, polysaccharides are depolymerized to their associated proteins by incubation with hydrazine. Glycans were released from the proteins (Ludger Hydrazinolysis Glycan Release Kit, Oxfordshire, UK). Hydrazine, a nucleophile, acts as a nucleophilic bond between the polysaccharide and the carrier protein. It attacks the glycosidic bond, releasing the attached glycan. The N-acetyl group is During the course of glycan synthesis, free glycans are lost and must be reconstituted by re-N-acetylation. , purified on a carbon column, and subsequently reduced with the fluorophore 2-aminobenzamide. The ends can be labeled. Labeled polysaccharides can be prepared as described in Royle et al., Anal Biochem 2002, 304(1). The peptides could be separated on a GlycoSep-N column (GL Sciences) according to the HPLC protocol of :70-90. The resulting fluorescence chromatogram indicates the length and number of repeating units of the polysaccharide. Structural information was gathered by collecting individual peaks and subsequent MS / MS analysis. This allows the monosaccharide composition and sequence of the repeating units to be ascertained. The low molecular weight specific peaks are the basis for the identification of the homogeneity of the polysaccharide composition. The glycan sequences can be analyzed by I-MS / MS and the results used to confirm the sequence. Each peak corresponds to a polymer consisting of a particular number of repeating units and their fragments. Thus, the chromatogram allows the determination of the polymer length distribution. The elution time is an indication of the polymer length, while the fluorescence intensity is an indication of the molar abundance for each polymer. It correlates with the amount present.

[0077] The uniformity of the glycan patterns associated with proteins is a function of glycan length and glycosylation site. This uniformity can be measured by methods known in the art since it is related to the number of glycans present overall. can be assessed using methods that measure, for example, glycan length and hydrodynamic radius. Size exclusion HPLC allows the measurement of hydrodynamic radius. Glycosylation sites in proteins The higher the number of glycosylation sites, the greater the hydrodynamic radius compared to carriers with fewer glycosylation sites. However, when single glycan chains are analyzed, they are The glycan length can be more uniform because the length is more highly controlled. This can be measured by digestion, SDS PAGE, and capillary gel electrophoresis. Uniformity also indicates that the usage pattern of a particular glycosylation site is broader or narrower. These factors can be measured by glycopeptide LC-MS / MS. This can be done.

[0078] N-glycosylation confers a number of benefits to HuGlyIDUA used in the methods described herein. Such benefits are not achievable by protein production in E. coli. This is because E. coli does not naturally possess the components required for N-glycosylation. Furthermore, some benefits are not accessible by protein production in e.g. CHO cells. It is believed that CHO cells express the necessary components for the addition of certain glycans (e.g., 2,6 sialic acid). Glycans that lack the 5'-terminal nucleotide and are not typical for humans, such as Neu5Gc and most individual The α-Gal antigen is immunogenic in the body and can induce anaphylaxis at high concentrations. Therefore, expression of IDUA in human neuronal or glial cells may result in Otherwise, when produced in CHO cells or E. coli, it is not associated with the protein. HuGlyIDUA is produced, which contains beneficial glycans that may be useful for the synthesis of glycans that are highly soluble in glycans of the glycan complex.

[0079] 5.1.2. Tyrosine Sulfation In addition to the N-linked glycosylation sites, hIDUA contains the N-glycosylation sites required for binding and activity. 372 Includes Tyrosine ("Y") sulfation site near the domain [ka] (See, e.g., Protein Tyrosine Sulfation, Analysis of the amino acids surrounding the tyrosine residues that are affected by the tyrosine residues in Yang et al., 2015, Molecular Biology. les 20:2138-2164, especially p. 2154. The "Rules" can be summarized as follows: The Y residue has E or D within the +5 to -5 positions from Y, and the -1 position of Y is neutral or acidic. - a neutral charged amino acid, but not a basic amino acid, such as R, K, or H, that disables sulfation Without intending to be bound by any theory, it is believed that It is known that mutations in the IL-1 gene (e.g., W306L) are associated with reduced enzyme activity and disease. , sulfation of this site in hIDUA may be crucial for activity. (Maita et al., 2013, PNA S 110:14628, pp. 14632-14633).

[0080] Importantly, tyrosine sulfation proteins naturally express the enzymes required for tyrosine sulfation. In addition, CHO cells cannot produce tyrosine sulfate. Defective in post-translational tyrosine sulfation - these cells are not secretory cells and undergo post-translational tyrosine sulfation See, e.g., Mikkelsen and Ezban, 1991, Biochemistry 30:1 533-1537. Advantageously, the methods provided herein are secretory and Indeed, IDUA in neurons or glial cells with the capacity for tyrosine sulfation, e.g. For example, it requires expression of HuGlyIDUA. Assays for detecting tyrosine sulfation are described in the art. These methods are well known in the art. See, for example, Yang et al., 2015, Molecules 20:2138-2164. I want to be illuminated.

[0081] Tyrosine sulfation of hIDUA, an active post-translational process in human CNS cells, enhances the expression of transgene products. The processing and activity of lysosomal proteins should be improved. The significance of this modification remains unclear; however, in other proteins, tyrosine sulfation has been shown to modulate It increases the affinity of protein-protein interactions (antibodies and receptors) and It has been shown to enhance the degradative processing of peptide hormones (Moore, 20 03, J Biol. Chem. 278:24243-46; and Bundegaard et al., 1995, EMBO J 14: 3073-79. (See ). Tyrosine sulfation (which occurs as the final step in IDUA processing) Tyrosine protein sulfotransferase 1 (TPST1), which is responsible for the Gene expression data for T1 can be accessed at, for example, http: / / www.ebi.ac.uk / gxa / home (which can be found in the EMBL-EBI Expression Atlas) at higher levels (based on mRNA Such post-translational modifications are at best expressed in the CHO cell product, laronida is underrepresented in

[0082] 5.2 Constructs and Formulations A viral vector encoding α-L-iduronidase (IDUA), e.g., human IDUA (hIDUA), or Other DNA expression constructs for use in the methods provided herein include The viral vectors and other DNA expression constructs provided herein The methods include any suitable method for delivering a transgene to the cerebrospinal fluid (CSF). Vehicles for gene delivery include viral vectors, liposomes, other lipid-containing complexes, and other high-performance Molecular complexes, synthetic modified mRNA, unmodified mRNA, small molecules, non-bioactive molecules (e.g. gold particles), heavy Synthetic molecules (e.g. dendrimers), naked DNA, plasmids, phages, transposons In some embodiments, the vector is a targeting vector. vectors (e.g., vectors that target neural cells).

[0083] In some embodiments, the disclosure provides a nucleic acid for use encoding an IDUA, e.g., a hIDUA. The nucleic acid comprises a cytomegalovirus (CMV) promoter, a Rous sarcoma virus (RSV) promoter, promoter, MMT promoter, EF-1α promoter, UB6 promoter chicken β-actin The chin promoter, CAG promoter, RPE65 promoter, and opsin promoter The promoter is operably linked to a promoter selected from the group consisting of:

[0084] In certain embodiments, a recombinant vector comprising one or more nucleic acids (e.g., polynucleotides) is Nucleic acid can include DNA, RNA, or a combination of DNA and RNA. In one embodiment, the DNA comprises a promoter sequence, a gene sequence of interest (transfection One or more sequences selected from the group consisting of a gene (e.g., IDUA), an untranslated region, and a termination sequence. In some embodiments, the viral vectors provided herein are It comprises a promoter operably linked to an elephant gene.

[0085] In certain embodiments, the nucleic acids (e.g., polynucleotides) and The nucleic acid sequence may be codon-optimized, for example, via any codon-optimization technique known to one of skill in the art. (See, e.g., review by Quax et al., 2015, Mol Cell 59:149-161. sea ​​bream).

[0086] (5.2.1. mRNA) In some embodiments, the vectors provided herein can be used to express a gene of interest (e.g., For example, modified mRNA encoding a transgene, e.g., IDUA. Synthesis of modified and unmodified mRNA for delivery of a polypeptide is described, for example, in the entirety of the present invention. Incorporated article by Hocquemiller et al., 2016, Human Gene Therapy 27(7):478-496 In one embodiment, a modification encoding IDUA, e.g., hIDUA, is provided herein. mRNA is provided herein.

[0087] 5.2.2. Viral Vectors Viral vectors include adenoviruses, adeno-associated viruses (AAV, e.g., AAV9), Lentivirus, helper-dependent adenovirus, herpes simplex virus, poxvirus viruses, Sendai virus (hemagglutinin virus of Japan) (HVJ), alphaviruses, There are two types of vectors: mitogenic virus, mitogenic vector, and retroviral vector. Retroviral vectors include: There are murine leukemia virus (MLV) and human immunodeficiency virus (HIV)-based vectors. Lufa virus vectors include Semliki Forest virus (SFV) and Sindbis virus (SIN). In some embodiments, the viral vectors provided herein are recombinant. In one embodiment, the virus provided herein is a viral vector. The vector is engineered to be replication-deficient in humans. , viral vectors include hybrid vectors, e.g., "helpless" adenoviruses. In one embodiment, the first virus is an AAV vector that is placed in the vector. A virus containing a viral capsid and a viral envelope protein from a second virus. In a specific embodiment, a second virus vector is provided herein. In a more specific embodiment, the virus is a vesicular stomatitis virus (VSV). The target protein is the VSV-G protein.

[0088] In certain embodiments, the viral vectors provided herein are HIV-based In one embodiment, the HIV-based vector provided herein is a viral vector. The vector comprises at least two polynucleotides, wherein the gag and pol genes are HIV gag genes. The gene is derived from the host virus, and the env gene is derived from another virus.

[0089] In some embodiments, the viral vectors provided herein are directed to herpes simplex In one embodiment, the present invention provides a method for the preparation of a human ovarian cancer cell line comprising administering to the patient .... The provided herpes simplex virus-based vector does not contain one or more immediate early (IE) genes, To achieve this, the antibody is modified to eliminate its cytotoxicity.

[0090] In one embodiment, the viral vector provided herein is an MLV-based In one embodiment, the MLV-based vectors provided herein are The vectors contain up to 8 kb of heterologous DNA in place of the viral genes.

[0091] In some embodiments, the viral vector provided herein is a lentivirus. In one embodiment, the present invention provides a method for the preparation of a therapeutic agent for the treatment of a disease comprising administering to a patient a therapeutically effective amount of the therapeutic agent provided herein. The lentiviral vector is derived from a human lentivirus. The lentiviral vectors provided herein are derived from non-human lentiviruses. In one embodiment, the lentiviral vector provided herein is In one embodiment, the virus is packaged in a virus capsid as provided herein. The lentiviral vector provided contains the following elements: long terminal repeats, primer binding sites It contains one or more of a binding site, a polypurine tract, an att site, and an encapsidation site.

[0092] In some embodiments, the viral vectors provided herein are alphavirus. In one embodiment, the vectors provided herein are vectors based on the HIV-1 virus. The alphavirus vector is a recombinant, replication-defective alphavirus. In the manner described herein, the alphavirus vectors Precons specifically bind to virions by displaying functional heterologous ligands on their virion surface. The antibody is targeted to a specific cell type.

[0093] In one embodiment, the viral vector provided herein is an AAV-based In a preferred embodiment, the viruses provided herein are In one embodiment, the viral vector is an AAV9 or AAVrhlO based viral vector. The AAV9 or AAVrhlO-based viral vectors provided herein are capable of infecting CNS cells. Several AAV serotypes have been identified. The AAV-based vectors provided in contain components derived from one or more serotypes of AAV. In some embodiments, the AAV-based vectors provided herein include AAV1, AAV2, , AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrhlO, or AAV11. In a preferred embodiment, the AAV-based vectors provided herein The AAV9-based vector contains components derived from one or more of the AAV8, AAV9, AAV10, or AAV11 serotypes. Viral vectors are used in the methods described herein. AAV-based viral vectors The nucleic acid sequences and methods for producing recombinant AAV and AAV capsids are described, for example, in their entireties, in No. 7,282,199 B2, U.S. Pat. No. 7,790,444, which are incorporated herein by reference. 9 B2, U.S. Patent No. 8,318,480 B2, U.S. Patent No. 8,962,332 B2 and International Patent Application No. PCT / In one embodiment, however, the transgene (e.g., ID AAV (e.g., AAV9 or AAVrh10)-based viral vectors encoding the .UA are described herein. In a specific embodiment, an AAV9-based viral vector encoding IDUA is provided. In a more specific embodiment, a vector encoding hIDUA is provided herein. Provided herein are AAV9-based viral vectors that

[0094] (i) An expression cassette containing a transgene under the control of regulatory elements and flanked by ITRs. and (ii) having the amino acid sequence of an AAV9 capsid protein or has at least 95%, 96%, 97%, 98%, 99%, or 99.9% identity with the amino acid sequence of the protein (SEQ ID NO: 26) % identical to the AAV9 capsid and at the same time retains the biological functions of the AAV9 capsid. In certain embodiments, an AAV9 vector is provided that comprises an artificial genome comprising In the above, the encoded AAV9 capsid is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63 , 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28 , 29, or 30 amino acid substitutions and retain the biological function of the AAV9 capsid. FIG. 5 shows substitutions at specific positions in the aligned sequences based on comparison in the column labeled Substitution. Amino acids of the capsid proteins of different AAV serotypes with potential amino acids that can be substituted A comparative alignment of sequences is provided. Thus, in a specific embodiment, the AAV9 vector comprises: 1, 2, 3, identified in the substitution sequence of FIG. 5 that is not present at that position in the native AAV9 sequence 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 , 26, 27, 28, 29, or 30 amino acid substitutions.

[0095] In certain embodiments, the AAV used in the methods described herein is incorporated by reference in its entirety. As described in Zinn et al., 2015, Cell Rep. 12(6):1056-1068, which is incorporated herein by reference, In one embodiment, the AAV used in the methods described herein is c80 or Anc80L65. No. 9,193,956, each of which is incorporated herein by reference in its entirety; Nos. 9,458,517; and 9,587,282, and as described in U.S. Patent Application Publication No. 2016 / 0376323. and comprises one of the following amino acid insertions: LGETTRP or LALGETTRP. No. 9,193,956, each of which is incorporated herein by reference in its entirety; Nos. 9,458,517; and 9,587,282, and U.S. Patent Application Publication No. 2016 / 0376323. As mentioned above, the AAV used in the methods described herein is AAV.7m8. The AAV used in the methods described herein can be any of the AAVs disclosed in U.S. Pat. No. 9,585,971. In one embodiment, the AAV can be any AAV that can be expressed by the methods described herein (e.g., AAV-PHP.B). The AAVs used are described in the following patents, each of which is incorporated herein by reference in its entirety: and patent applications: U.S. Patent Nos. 7,906,111; 8,524,446; 8,999,678; 8,628,966 No. 8,927,514; No. 8,734,809; U.S. No. 9,284,357; No. 9,409,953; No. 9,169,299; Nos. 9,193,956; 9,458,517; and 9,587,282, U.S. Patent Application Publication No. 2015 / 0374803; No. 2015 / 0126588; No. 2017 / 0067908; No. 2013 / 0224836; No. 2016 / 0215024; No. 2017 / No. 0051257; and International Patent Application Nos. PCT / US2015 / 034799; PCT / EP2015 / 053335. The AAV disclosed herein is

[0096] In some embodiments, single-stranded AAV (ssAAV) can be used as described above. In embodiments, a self-complementary vector, such as an scAAV, can be used (e.g. and Wu, 2007, Human Genetics, each of which is incorporated by reference in its entirety. Therapy, 18(2):171-82. McCarty et al., 2001, Gene Therapy, Vol 8, Number 16, 1 See pages 248-1254; and U.S. Patent Nos. 6,596,535; 7,125,717; and 7,456,683. (I want to be).

[0097] In certain embodiments, the viral vector used in the methods described herein is an adenovirus. Recombinant adenovirus vectors are used to deliver IDUA. The recombinant adenovirus can be used for transfection. and an expression cassette is inserted into any deleted region. The recombinant adenovirus can be a vector for the next generation of adenoviruses. The helper-dependent adenovirus may be a second generation vector comprising an adenovirus reverse transcription factor (RTF) vector. Only the oriented terminal repeat sequence and the packaging signal (φ) are retained. The insert is between the caging signal and the 3'ITR and is approximately 36 kb in size, close to the wild type. It may or may not have stuffer sequences that maintain the genome. Exemplary protocols for the production of viral vectors are set forth herein, in their entirety. Alba et al., 2005, "Weakening Adenoviruses: A Novel Approach to Gene Therapy," Gutless adenovirus: last generation adenovirus for gene therapy Herapy," Gene Therapy 12:S18-S27.

[0098] In certain embodiments, the viral vector used in the methods described herein is a lentivirus. A recombinant lentiviral vector is a virus-based vector that is used to deliver IDUA. Four plasmids were used for the construct: plasmids containing Rev sequences, plasmids containing envelope proteins (i.e. We created a Cis plasmid carrying the VSV-G gene, as well as packaging elements and the IDUA gene. Used to manufacture.

[0099] For the production of lentiviral vectors, polyethylenimine or calcium phosphate are particularly preferred. The four plasmids can be delivered to cells (i.e. The cells are then co-transfected with lentivirus vectors (i.e., HEK293-based cells). Harvest the cells (lentiviruses need to bud from the cells to be active). (It is not necessary and should not be harvested from the cells). The supernatant is filtered (0.45 μm) Magnesium chloride and benzonase are then added. Further downstream processes vary greatly. There are many different possibilities, with the use of TFF and column chromatography being the most GMP-compliant process. Other processes use ultracentrifugation and involve column chromatography. An exemplary protocol for the production of lentiviral vectors is shown below. Coll is described in Lesch et al., 2002, both of which are incorporated by reference in their entireties. 011, "Lentiviruses generated in 293T suspension cells using baculovirus vectors Production and purification of lentiviral vector generation d in 293T suspension cells with baculoviral vectors)”, Gene Therapy 18:531-538 and Ausubel et al., 2012, "CGMP-Grade Lentiviral Vector Production" of CGMP-Grade Lentiviral Vectors,” Bioprocess Int. 10(2):32-43. Cut.

[0100] In a specific embodiment, the vector used in the methods described herein is an IDUA (e.g., For example, hIDUA) and expressing the vector in a cell of the CNS or a related cell (e.g., in vivo When transduced into human neurons in vitro, glycosylated variants of IDUA were found to be transfected In a specific embodiment, the present invention provides a method for the production of a nucleic acid sequence that is expressed by a cell into which it is introduced. The vector used in the methods described herein is a vector encoding IDUA (e.g., hIDUA). and transducing cells of the CNS or associated cells (e.g., neurons in vivo or in vitro). Upon transduction, the sulfated variant of IDUA is expressed by the cells.

[0101] 5.2.3. Promoters and Modifiers of Gene Expression In some embodiments, the vectors provided herein are used for gene delivery or In some embodiments, the expression control element is a regulated expression control element. Thus, the vectors provided herein contain components that regulate gene expression. In embodiments, the vectors provided herein affect binding to cells. In some embodiments, the method comprises the steps of: The vectors are designed to localize the polynucleotide (e.g., transgene) within the cell after uptake. In some embodiments, the vectors provided herein include components that affect the catalysis of the vectors. The vector can be used, for example, to detect or select cells that have taken up the polynucleotide. The present invention includes a component that can be used as a detectable or selectable marker for the gene.

[0102] In certain embodiments, the viral vectors provided herein comprise one or more promoters. In one embodiment, the promoter is a constitutive promoter. In an alternative embodiment, the promoter is an inducible promoter. The genes, like most housekeeping genes, predominantly use GC-rich promoters In a preferred embodiment, a strong constitutive promoter that provides sustained expression of hIDUA is used. Such promoters include: "C" - Cytomegalovirus (CMV) promoter "A" - promoter and first enhancer element of chicken β-actin gene Exons and introns; and "G" - splice access of rabbit β-globin gene There is a synthetic promoter called "CAG" that contains a nucleotide sequence similar to that of the promoter described in Miyazaki et al., 1989, Gene 79: 269-270. 77; and Niwa et al., Gene 108:193-199).

[0103] In one embodiment, the promoter is the CB7 promoter (herein incorporated by reference in its entirety). See Dinculescu et al., 2005, Hum Gene Ther 16:649-663, incorporated herein by reference. In some embodiments, the CB7 promoter is driven by a vector. In some embodiments, the expression control elements include other expression control elements that enhance expression of the transgene. Other expression control elements include chicken β-actin intron and / or rabbit β-actin intron. In one embodiment, the promoter contains a TATA box. In some embodiments, the promoter comprises one or more elements. In such a case, one or more promoter elements may be positioned in opposite directions relative to each other. In some embodiments, the elements of the promoters function cooperatively. In some embodiments, the elements of the promoter are arranged to function independently. In one embodiment, the viral vectors provided herein are are human CMV immediate early gene promoter, SV40 early promoter, and Rous sarcoma virus (RS) promoter. one or more selected from the group consisting of long terminal repeat and rat insulin promoter In one embodiment, the vector provided herein comprises a promoter of One or more selected from the group consisting of AAV, MLV, MMTV, SV40, RSV, HIV-1, and HIV-2 LTR In one embodiment, the promoter of the present invention comprises a long terminal repeat (LTR) promoter of the The vectors provided herein may contain one or more tissue-specific promoters (e.g., a neuronal cell-specific promoter). Includes the motor.

[0104] In certain embodiments, the viral vectors provided herein comprise one or more promoters. In some embodiments, the methods provided herein include regulatory elements other than the motor. In some embodiments, the viral vector described herein comprises an enhancer. The viral vectors provided herein comprise a repressor. The viral vectors provided herein contain an intron or a chimeric intron. In some embodiments, the viral vectors provided herein contain a polyadenylation sequence. nothing.

[0105] 5.2.4. Signal Peptides In some embodiments, the vectors provided herein regulate protein delivery. In one embodiment, the viral vectors provided herein include components that In one embodiment, the signal peptide comprises one or more signal peptides. Proper packaging (e.g., glycosylation) of the transgene product (e.g., IDUA) within the cell In one embodiment, the signal peptide allows the transgene This allows the product (e.g., IDUA) to achieve proper localization within the cell. In the present invention, a signal peptide is used to achieve secretion of a transgene product (e.g., IDUA) from a cell. Examples of signal peptides that may be used in conjunction with the vectors and those described herein include The transgenes provided herein can be found in Table 1. In the specification, it may be referred to as a leader sequence or leader peptide. Table 1. Signal peptides for use with the vectors provided herein. [Table 1]

[0106] (5.2.5. Untranslated Regions) In certain embodiments, the viral vectors provided herein include one or more non-translated In some embodiments, the UTR comprises a 3′ and / or 5′ UTR. In one embodiment, the UTRs are optimized for a desired level of protein expression. In one embodiment, the UTR is optimized for the mRNA half-life of the transgene. In one embodiment, the UTRs are optimized for RNA stability. Optimized for secondary structure.

[0107] 5.2.6. Inverted terminal repeats In certain embodiments, the viral vectors provided herein comprise one or more reverse transcription The ITR sequence is responsible for the expression of the recombinant gene in the virion of the viral vector. It can be used to package the current cassette. In one embodiment, The ITRs are derived from an AAV (e.g., AAV9), each of which is incorporated herein by reference in its entirety. , e.g., Yan et al., 2005, J. Virol., 79(1):364-379; U.S. Pat. 7,282,199 B2, U.S. Patent No. 7,790,449 B2, U.S. Patent No. 8,318,480 B2, U.S. Patent No. 8, (See, for example, Patent Application No. PCT / EP2014 / 076466).

[0108] 5.2.7. Transgenes In one embodiment, the vector provided herein encodes an IDUA transgene. In a specific embodiment, IDUA is encoded by an expression control enzyme suitable for expression in neuronal cells. In one embodiment, the IDUA (e.g., hIDUA) transgene is regulated by , comprising the amino acid sequence of SEQ ID NO: 1. In one embodiment, the IDUA (e.g., hIDUA)-introduced The gene has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 1 It comprises an amino acid sequence that is 2%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical.

[0109] The HuGlyIDUA encoded by the transgene may be selected from the group consisting of, but not limited to, SEQ ID NO: 1, human IDUA (hIDUA) having the amino acid sequence of For example, but not limited to, the orthologue of IDUA shown in FIG. The present invention may include derivatives of hIDUA that contain amino acid substitutions selected from non-conserved residues corresponding to Such mutations are shown in FIG. 3 (Sa Ito et al., 2014, Mol Genet Metab 111:107-112, Table 1 listing 57 MPS I mutations or Venturi et al., each of which is incorporated herein by reference in its entirety. 2002, Human Mutation #522 Online ("Venturi 2002"), or Bertola et al., 201 1, severe, moderate, as reported by Human Mutation 32:E2189-E2210 ("Bertola 2011"); Any mutations identified in more severe, moderate, or attenuated MPS I phenotypes (Provided that it does not include

[0110] For example, amino acid substitutions at specific positions in hIDUA are shown in FIG. 2, which is incorporated herein by reference in its entirety. The ortholog reported in Maita et al. (2013, PNAS 110:14628, Figure S8) The corresponding sequence found at that position in the IDUA orthologue shown in The substitutions may be selected from non-conserved amino acid residues as shown in FIG. or deleterious mutations reported in Venturi 2002 or Bertola 2011, supra. The resulting transgene product is then incubated in cell culture for 1 h. In culture or in test animals, in vitro to ensure that the mutation does not impair IDUA function The preferred amino acid substitutions selected can be tested using conventional assays. Deletions or additions can be used in conventional in vitro assays for MPS I in cell culture or animal models. Maintain or increase the enzymatic activity, stability, or half-life of the IDUA tested by the assay. For example, the enzymatic activity of the transgene product should be such that it does not The results were evaluated using a conventional enzyme assay with umbelliferyl α-L-iduronide. (For exemplary IDUA enzyme assays that can be used, see, for example, Hopwood et al., 1979, Clin Chim Acta 92: 257-265; Clements et al., 1985, Eur J Biochem 152: 21-28; and Kakkis et al., 19 94, Prot Exp Purif 5:225-232. The ability to transfect MPS I cells in culture with a viral vector encoding hIDUA or a derivative; or other DNA expression constructs; or by injecting MPS I cells with rHuGlyIDUA or a derivative; and co-culturing with human host cells engineered to secrete IgG1 and IgG2, to correct the defect in MPS I cultured cells. For example, by determining IDUA enzyme activity and / or GAG storage in MPS I cells in culture. The respective Myerowitz and Neufeld, 1981, J. Biol Chem 256: 3044-3048; and Anson et al., 1992, Hum Gene Ther 3: 371-379. I want to be illuminated.

[0111] (5.2.8. Constructs) In one embodiment, the viral vector provided herein comprises the following sequence: a) a first ITR sequence; b) a first linker sequence; c) a promoter sequence; d) a second linker sequence, e) an intron sequence, f) a third linker sequence, and g) a transgene (e.g. For example, a sequence encoding IDUA, h) a fourth linker sequence, i) a polyA sequence, j) a fifth linker sequence, - sequence, and k) the second ITR sequence.

[0112] In one embodiment, the viral vector provided herein comprises a nucleic acid sequence comprising: The following elements: a) a promoter sequence, and b) a sequence encoding a transgene (e.g., IDUA). In one embodiment, the viral vectors provided herein comprise a sequence comprising: The following elements, in the following order: a) a promoter sequence, and b) a transgene (e.g., IDU). A) wherein the transgene includes a signal peptide.

[0113] In one embodiment, the viral vector provided herein comprises a nucleic acid sequence comprising: The following elements: a) the first ITR sequence, b) the first linker sequence, c) the promoter sequence, d) a) a second linker sequence; e) an intron sequence; f) a third linker sequence; g) a first UTR sequence; h) a sequence encoding a transgene (e.g., IDUA), i) a second UTR sequence, j) a fourth linker sequence. , k) a polyA sequence, l) a fifth linker sequence, and m) a second ITR sequence.

[0114] In one embodiment, the viral vector provided herein comprises the following sequence: a) a first ITR sequence; b) a first linker sequence; c) a promoter sequence; d) a second linker sequence; e) an intron sequence; f) a third linker sequence; g) a first UTR sequence; h) a sequence encoding a transgene (e.g., IDUA); i) a second UTR sequence; j) a fourth linker sequence. k) a polyA sequence, l) a fifth linker sequence, and m) a second ITR sequence, The gene contains a signal peptide and encodes hIDUA.

[0115] 5.2.9. Vector Production and Testing The viral vectors provided herein can be produced using host cells. The viral vectors provided herein can be expressed in mammalian host cells, such as A5 49, WEHI, 10T1 / 2, BHK, MDCK, COS1, COS7, BSC 1, BSC 40, BMT 10, VERO, W138, HeLa , 293, Saos, C2C12, L, HT1080, HepG2, primary fibroblasts, hepatocytes and myoblasts) The viral vectors provided herein can be produced in a variety of ways, including in vivo expression levels in humans, monkeys, and the like. It can be produced using host cells from mice, rats, rabbits, or hamsters. do.

[0116] The host cell contains the transgene and associated elements (i.e., the vector genome), and the A means for producing the virus in a host cell, such as replication and capsid genes (e.g., rep The vector is stably transformed with a sequence encoding the AAV8 capsid (and cap gene). Methods for producing recombinant AAV vectors are described in detail in the entirety of which are incorporated herein by reference. See Section IV of the Detailed Description of U.S. Patent No. 7,282,199 B2, incorporated herein by reference. The genome copy titer of the target gene can be determined, for example, by TAQMAN® analysis. Virions can be isolated by, for example, CsCl 2 It can be recovered by settling.

[0117] In vitro assays, such as cell culture assays, may be used to detect the introduction of Can be used to measure gene expression and thus indicate, for example, the efficacy of a vector For example, HT-22, SK-N-MC, HCN-1A, HCN-2, NT2, SH-SY5y, hNSC11, or R eNcell VM cell line, or neuronal or glial cells, or neuronal or glial cells Use other cell lines derived from the precursor cells of the cells to assess transgene expression. Once expressed, glycosylation and tyrosine sulfate associated with HuGlyIDUA are Characterize the expressed product (i.e., HuGlyIDUA), including determining the expression pattern. This can be done.

[0118] (5.2.10. Composition) A composition comprising a vector encoding a transgene as described herein and a suitable carrier. Suitable carriers (e.g., CSF, and, for example, for administration to neural cells) will be described by those of skill in the art. is easily selected by

[0119] (5.3 Gene Therapy) Methods for administering a therapeutically effective amount of a transgene construct to a human subject having MPS I. More specifically, a method is described in which a patient with MPS I is administered a therapeutically effective amount of a transgene construct. Methods for administering lactate, particularly to the CSF, are described. In accordance with the present invention, a method for administering a therapeutically effective amount of such a transgene construct to the CSF is for use in treating patients with Hurler syndrome or Hurler-Scheie syndrome It is possible.

[0120] 5.3.1. Target Patient Population In one embodiment, a therapeutically effective dose of the recombinant vector is administered to a patient diagnosed with MPS I. In a specific embodiment, the patient has been diagnosed with Hurler-Scheie syndrome. In a specific embodiment, the patient has been diagnosed with Scheie syndrome. In this study, the patient was diagnosed with Hurler syndrome.

[0121] In one embodiment, a therapeutically effective dose of the recombinant vector is administered to a subject diagnosed with severe MPS I. In one embodiment, a therapeutically effective dose of the recombinant vector is administered to a patient. It is administered to patients diagnosed with I.

[0122] In one embodiment, a therapeutically effective dose of the recombinant vector is administered to a patient diagnosed with MPS I and receiving IDUA ( For example, it is administered to patients identified as responding to treatment with hIDUA.

[0123] In some embodiments, a therapeutically effective dose of the recombinant vector is administered to a pediatric patient. In an embodiment, a therapeutically effective dose of the recombinant vector is administered to a patient who is under the age of 3. In one embodiment, a therapeutically effective dose of the recombinant vector is administered to a patient who is between 2 and 4 years of age. In one embodiment, a therapeutically effective dose of the recombinant vector is administered to a patient who is between 3 and 8 years of age. In one embodiment, a therapeutically effective dose of the recombinant vector is administered to a patient who is between 8 and 16 years of age. In one embodiment, a therapeutically effective dose of the recombinant vector is administered to a patient who is between 6 and 18 years of age. In one embodiment, a therapeutically effective dose of the recombinant vector is administered to a subject who is 6 years of age or older. In one embodiment, a therapeutically effective dose of the recombinant vector is administered to a patient under the age of 3. In one embodiment, a therapeutically effective dose of the recombinant vector is administered to a patient at least 4 months of age. In one embodiment, a therapeutically effective dose of The recombinant vector is administered to a patient who is at least 9 months of age but less than 18 months of age. In an embodiment, a therapeutically effective dose of the recombinant vector is administered to a patient who is 18 months or older but less than 3 years old. In one embodiment, a therapeutically effective dose of the recombinant vector is administered to a subject over the age of 10. In one embodiment, a therapeutically effective dose of the recombinant vector is administered to an adolescent patient. In one embodiment, a therapeutically effective dose of the recombinant vector is administered to an adult patient. Administer.

[0124] In one embodiment, a therapeutically effective dose of the recombinant vector is administered to a patient diagnosed with MPS I and having Patients identified as responding to treatment with IDUA (e.g., hIDUA) infused into the CSF prior to treatment Administer to patients who have

[0125] 5.3.2. Dosage and Mode of Administration In one embodiment, the therapeutically effective dose of the recombinant vector is administered intrathecally (i.e., After injection into the subarachnoid space, the recombinant vector is dispersed through the CSF and transduces cells in the CNS. This can be done in a number of ways, including For example, this can be accomplished by intracranial (cisternal or ventricular) injection, or by injection into the lumbar cisterna. In certain embodiments, intrathecal administration is performed by intracisternal (IC) injection (e.g., into the cisterna magna). In a specific embodiment, intracisternal injection is performed by CT-guided suboccipital puncture. In a specific embodiment, intrathecal injection is performed by lumbar puncture. In a specific embodiment, injection into the subarachnoid space is performed if feasible for the patient. is performed by C1-2 puncture. In one embodiment, the therapeutically effective dose of the recombinant vector is In one embodiment, a therapeutically effective dose of the recombinant vector is administered to the CNS via intranasal administration. The vector is administered to the CNS by intraparenchymal injection. In one embodiment, the intraparenchymal injection is In one embodiment, the intraparenchymal injection targets the striatum. In one embodiment, the intraparenchymal injection targets the white matter. In embodiments, a therapeutically effective dose of the recombinant vector is administered by any means known in the art, e.g. See, for example, Hocquemiller et al., 2016, Hu et al., which are incorporated by reference in their entireties. The antibody may be administered to the CSF by any of the means disclosed in J. Med. Gene Therapy 27(7):478-496. do.

[0126] The recombinant vector should be incubated at a CSF concentration of at least 9.25–277 μg / mL of rHuGlyIDUA. min Maintained In one embodiment, the recombinant vector is CSF concentrations of GlyIDUA should be at least 9.25, 16, 46, 92, 185, or 277 μg / mL) min Maintained In one embodiment, the recombinant vector is administered to the CSF at a dose that is in the range of rHuGlyIDUA to rHuGlyIDUA. SF concentrations of at least 9.25, 16, 46, 92, 185, or 277 μg / mL) min at a dose that maintains In one embodiment, the recombinant vector is administered to the CSF to reduce the CSF concentration of rHuGlyIDUA. C of at least 9.25 μg / mL min In one embodiment, the CSF is administered at a dose that maintains the patient at a constant level. The recombinant vector was incubated at a CSF concentration of at least 16 μg / mL of rHuGlyIDUA. min at a dose that maintains In one embodiment, the recombinant vector is administered to the CSF to reduce the CSF concentration of rHuGlyIDUA. C of at least 46 μg / mL min In one embodiment, the composition is administered to the CSF in a dose that maintains the patient's immune status. The recombinant vector was incubated at a CSF concentration of at least 92 μg / mL of rHuGlyIDUA. min At a dose that maintains In one embodiment, the recombinant vector is administered to the CSF to reduce the CSF concentration of rHuGlyIDUA. C of at least 185 μg / mL min In one embodiment, the composition is administered to the CSF in a dose that maintains the patient's immune status. The recombinant vector was incubated at a CSF concentration of at least 277 μg / mL of rHuGlyIDUA. min at a dose that maintains , and administered into the CSF.

[0127] In one embodiment, for pediatric patients, the recombinant vector is expressed as total rHuGlyIDUA In one embodiment, the pediatric patient is administered a dose of 1.00 to 30.00 mg of For each of the three recombinant vectors, the total rHuGlyIDUA in the CSF was 1.00, 1.74, 5.00, 10.00, and 20.00. or 30.00 mg in the CSF. To achieve this, the recombinant vector was administered to the CSF at a dose that maintained 1.00 mg total rHuGlyIDUA in the CSF. In one embodiment, for pediatric patients, the recombinant vector is expressed in CSF as total rHuGlyI. The DUA is administered into the CSF at a maintenance dose of 1.74 mg. To achieve this, the recombinant vector was administered to the CSF at a dose that maintained 5.00 mg total rHuGlyIDUA in the CSF. In one embodiment, for pediatric patients, the recombinant vector is expressed in CSF as total rHuGlyI. The DUA is administered into the CSF at a maintenance dose of 10.00 mg. To achieve this, the recombinant vector was administered to the CSF at a dose that maintained total rHuGlyIDUA in the CSF at 20.00 mg. In one embodiment, for pediatric patients, the recombinant vector is expressed in CSF as total rHuGlyI. The DUA will be administered into the CSF at a maintenance dose of 30.00 mg.

[0128] In one embodiment, for an adult patient, the recombinant vector comprises total rHuGlyIDUA In one embodiment, the adult patient is administered a dose of 1.29 to 38.88 mg of For each of the three, the recombinant vector reduced the total rHuGlyIDUA in the CSF by 1.29, 2.25, 8.40, 12.96, and 25.93. or 38.88 mg into the CSF. To achieve this, the recombinant vector was administered to the CSF at a dose that maintained total rHuGlyIDUA in the CSF at 1.29 mg. In one embodiment, for adult patients, the recombinant vector is The DUA is administered into the CSF at a maintenance dose of 2.25 mg. To achieve this, the recombinant vector was administered into the CSF at a dose that maintained total rHuGlyIDUA in the CSF at 8.40 mg. In one embodiment, for adult patients, the recombinant vector is The DUA is administered into the CSF at a maintenance dose of 12.96 mg. To achieve this, the recombinant vector was administered into the CSF at a dose that maintained total rHuGlyIDUA in the CSF at 25.93 mg. In one embodiment, for adult patients, the recombinant vector is yIDUA will be administered into the CSF at a maintenance dose of 38.88 mg.

[0129] For intrathecal administration, the therapeutically effective dose of the recombinant vector is preferably adjusted to a volume of injection of A maximum of approximately 20 mL should be administered into the CSF. Elliots B solution should be used as a vehicle for recombinant vectors. Solution (generic name: sodium chloride, sodium bicarbonate, anhydrous glucose, magnesium sulfate, salt potassium chloride, calcium chloride, and sodium phosphate) are free of bacteriostatic preservatives. It is a non-pyrogenic, isotonic solution of the bacterium β-lactamase, which is used as a diluent for intrathecal administration of chemotherapy drugs. and use.

[0130] CSF concentrations were determined by directly measuring the concentration of rHuGlyIDUA in CSF fluid obtained via occipital or lumbar puncture. The concentration of rHuGlyIDUA detected in the patient's serum was monitored by In one embodiment, the serum rHuGlyIDUA concentration is 10 A range of ng / mL to 100 ng / mL indicates that the amount of rHuGlyIDUA in the CSF is 1 to 30 mg. In one embodiment, the recombinant vector maintains rHuGlyIDUA in serum at 10 ng / mL to 100 ng / mL. Administer into the CSF in a dose that will sustain the desired therapeutic effect.

[0131] In certain embodiments, the dosage is administered to the patient (e.g., via suboccipital puncture or lumbar puncture). In one embodiment, the number of genome copies administered to the CSF of the patient is measured. 1×10 12 ~2×10 14 In one embodiment, 5×10 genome copies are administered. 12 ~2×10 14 G In a specific embodiment, 1×10 13 ~1×10 14 Genome copies In a specific embodiment, 1×10 13 ~2×10 13 Inject a copy of the genome. In one embodiment, 6×10 13 ~8×10 13 A genome copy is administered.

[0132] In one embodiment, 1 × 10 13 A fixed dose of genome copies is administered to the pediatric patient. In one embodiment, 5.6×10 13 A fixed dose of genome copies is administered to the pediatric patient. In one embodiment, 1×10 12 ~5.6×10 13 A fixed dose of genome copies is administered to the pediatric patient. In one embodiment, 1×10 13 ~5.6×10 13 A fixed dose of genome copies is administered to pediatric patients. In one embodiment, 2.6×10 12 A fixed dose of genome copies is administered to adult patients In one embodiment, 1.3×10 13 A fixed dose of genome copies is administered to adult patients. In one embodiment, 1.4×10 13 A fixed dose of genome copies is administered to adult patients. In one embodiment, 7.0×10 13A fixed dose of genome copies is administered to an adult patient. In one embodiment, 1.4×10 13 ~7.0×10 13 A fixed dose of genome copies is administered to adult patients. In one embodiment, 1×10 12 ~5.6×10 13 A fixed dose of genome copies was administered to adult patients. Administer to the subject.

[0133] In one embodiment, the dosage is administered per gram of brain mass into the patient's CSF (e.g., The number of genome copies is measured (for example, by injecting the vaccine via suboccipital puncture or lumbar puncture). In one embodiment, 1×10 per gram of brain mass 9 ~2×10 10 A genome copy is administered. In one embodiment, 5×10 per gram of brain mass 9 ~2×10 10 Administering genome copies In one embodiment, 2×10 per gram of brain mass 9 A copy of the genome is administered. In an embodiment, 1×10 per gram of brain mass 10 Administer genome copies. In an embodiment, 9×10 per gram of brain mass 9 ~1×10 10 A copy of the genome is administered. In one embodiment, 1×10 per gram of brain mass 10 ~1.5×10 10 Administering genome copies In a specific embodiment, 5×10 per gram of brain mass 10 ~6×10 10 Inject genome copies Give.

[0134] In one embodiment, a non-replicating recombinant AAV of serotype 9 capsid comprising a hIDUA expression cassette ( rAAV9.hIDUA) is used for therapeutic purposes. Using the AAV9 serotype, hIDUA is expressed in the CNS after IC administration. This allows efficient protein expression. The vector genome contains the inverted terminal repeat (I The hIDUA expression cassette is flanked by a strong constitutive promoter. The inverter is driven by a

[0135] rAAV9.hIDUA is 1.4 × 10 in a volume of about 5-20 ml or less than about 5 ml. 13 GC(1.1×10 10 GC / g brain mass)~7.0×10 13 GC(5.6×10 10 As a single fixed dose over a range of GC / g brain mass It can be administered IC (by suboccipital injection) in patients who have neutralizing antibodies against AAV. If desired, higher dose ranges can be used. rAAV9.hIDUA is administered in a volume of approximately 5-20 ml. or 2.6 x 10 in a volume of about 5 ml or less 12 GC(2×10 9 GC / g brain mass)~1.3×10 13 GC(1×10 10 GC / IC (by suboccipital injection) as a single fixed dose over a range of g brain mass If the patient is 4 months or older but less than 9 months old, rAAV9.hIDUA should be delivered in a volume of approximately 5–20 mL. 6.0 x 10 in a volume of about 5 ml or less 12 GC(1.0×10 10 GC / g brain mass)~3.0×10 13 GC(5×1 0 10 Administered IC (by suboccipital injection) as a single fixed dose over a range of (GC / g brain mass) If the patient is 9 months or older but less than 18 months old, rAAV9.hIDUA can be administered in approximately 5 1.0 x 10 in a volume of ~20 ml or less than about 5 ml 13 GC(1.0×10 10 GC / g brain mass)~5.0×10 13 GC(5×10 10 IC (by suboccipital injection) as a single fixed dose over a range of GC / g brain mass If the patient is 18 months of age or older but less than 3 years of age, rAAV9.hIDUA is 1.1 x 10 in a volume of about 5 to 20 ml or less than about 5 ml. 13 GC(1.0×10 10 GC / g brain mass)~5. 5×10 13 GC(5×10 10 IC (suboccipital injection) as a single fixed dose over a range of GC / g brain mass It can be administered (by injection).

[0136] 5.4 Combination Therapy 5.4.1. Co-treatment with immunosuppressants While delivery of rHuGlyIDUA should minimize immune responses, gene therapy targeted to the CNS The most obvious potential source of toxicity for rheumatoid arthritis is the genetic deficiency of IDUA, and thus the protein and and / or in human subjects who are potentially intolerant of the vectors used to deliver the transgene. The aim of the present invention is to generate immunity against the hIDUA protein expressed in the host. In one embodiment, co-treating a patient with immunosuppressive therapy may be useful, particularly when IDUA levels are close to zero. - Appropriate when treating patients with severe disease (e.g., patients with Hurler syndrome) Tacrolimus or rapamycin (sirolimus) in combination with mycophenolic acid Immunosuppression with other immunosuppressive regimens used in tissue transplant procedures Such immunosuppressive therapy may be administered during the course of gene therapy. In some embodiments, pretreatment with immunosuppressive therapy may be preferred. Immunosuppressive therapy may be continued after gene therapy treatment at the discretion of the treating physician. If immune tolerance is subsequently induced, for example after 180 days, it may be discontinued.

[0137] In certain embodiments, the methods of treatment provided herein include prednisolone, mycobacterial In one embodiment, the therapeutic agent is administered in combination with an immunosuppressive regimen including phenolic acid and tacrolimus. The method of treatment provided herein includes administering prednisolone, mycophenolic acid, and and rapamycin (sirolimus). Therefore, the methods of treatment provided herein are similar to tacrolimus-free immunosuppressive regimens. In certain embodiments, the methods of treatment provided herein include administering one or more luticosteroids, such as methylprednisolone and / or prednisolone and tacrolimus In one embodiment, the therapeutic agent is administered in combination with an immunosuppressive regimen including limus and / or sirolimus. In accordance with the present invention, immunosuppressive treatment may be administered to the subject prior to or simultaneously with human IDUA treatment, such as (a) tacrolimus or (b) a combination of rapamycin and mycophenolic acid. In certain embodiments, the immunosuppressive treatment is continued for 180 days or more thereafter. In certain embodiments, immunosuppressive therapy is discontinued after 30, 60, 90, 120, 150, or 180 days. Discontinue after days.

[0138] In one embodiment, tacrolimus is administered at a dose to achieve a serum concentration of 5 to 10 ng / mL. In one embodiment, tacrolimus is administered at a dose to achieve a serum concentration of 4 to 8 ng / mL. In one embodiment, particularly when the patient is under 3 years of age, tacrolimus is administered at a serum concentration of In one embodiment, MMF is administered at a dose to achieve a serum concentration of 2 to 3.5 ng / mL. In one embodiment, tacrolimus is administered at a dose to achieve a serum concentration of 5 to 1 μg / mL. 0 ng / mL, and MMF is administered at a dose that results in a serum concentration of 2 to 3.5 μg / mL. In certain embodiments, serum concentrations are measured using trough levels of tacrolimus and / or MMF. This is achieved by titrating tacrolimus and / or MMF after the initial setting.

[0139] In one embodiment, methylprednisolone is administered intravenously once at a dose of 10 mg / kg. In one embodiment, prednisolone is administered orally once daily at a dose of 0.5 mg / kg. In some embodiments, prednisolone is tapered and then discontinued. In one embodiment, tacrolimus is administered at 100 mg / kg / day to maintain a target blood level of 4 to 8 ng / ml. 1 mg is administered orally twice daily. In some embodiments, particularly if the patient is under 3 years of age, Rolimus is administered orally at 0.05 mg / kg twice daily to maintain a target blood level of 2-4 ng / ml. In one embodiment, sirolimus is also administered. Patients are pre-administered with sirolimus and then Target blood levels can be maintained at 4-8 ng / ml throughout the regimen. In one embodiment, if the patient is under 3 years of age, the patient is preferably administered sirolimus. The patient is pre-dosed and then maintained at a target blood level of 1-3 ng / ml throughout the regimen. Methylprednisolone was administered intravenously once at a dose of 10 mg / kg, and prednisolone was administered once at a dose of 10 mg / kg. was orally administered once daily at a dose of 0.5 mg / kg, and tacrolimus was orally administered once daily at a dose of 0.2 mg / kg. and administer sirolimus.

[0140] In certain embodiments, rapamycin is administered orally once daily at a dose of 2 or 4 mg / kg. In one embodiment, MMF is administered orally at a dose of 25 mg / kg twice daily. Rapamycin was administered orally at a dose of 2 or 4 mg / kg once daily, and MMF was administered orally at a dose of 25 mg / kg once daily. In one embodiment, rapamycin is administered orally twice daily at a dose of 5 to 15 mg / kg. In one embodiment, MMF is administered at a dose to achieve a serum concentration of 2 to 3.5 μg / mL. In one embodiment, rapamycin is administered at a dose to maintain a serum concentration of 5 to 15 ng / mL. and MMF is administered at a dose that results in a serum concentration of 2 to 3.5 μg / mL. In an embodiment, the serum concentration is measured after measuring the trough levels of rapamycin and / or MMF. This is achieved by titration of mycin and / or MMF.

[0141] (5,4,2. Co-treatment with other treatments, including standard treatment) The combination of administering HuGlyIDUA to the CSF in conjunction with other available therapies: The method of the present invention includes administering additional treatments prior to, simultaneously with, or after the gene therapy treatment. The available treatments for MPS I that can be used in combination with the gene therapy of the present invention are Treatments include, but are not limited to, those using laronidase administered systemically or into the CSF. and / or HSCT therapy. In another embodiment, ERT is rHuGlyIDUA glycoprotein produced in a human cell line by recombinant DNA technology Such human glycoproteins can be used for the production of recombinant glycoproteins. Cell lines include, but are not limited to, HT-22, SK-N-MC, HCN-1A, HCN-2, to name a few. , NT2, SH-SY5y, hNSC11, ReNcell VM, human embryonic kidney 293 cells (HEK293), fibrosarcoma HT-1080, HKB-11, CAP, HuH-7, retinal cell line, PER.C6, or RPE (e.g., incorporated herein by reference in its entirety). The rHuGlyIDUA glycoprotein can be used for recombinant production of the glycoprotein. For a review of human cell lines, see Dumont et al., 2016, Critical Rev in Biotech 36(6): 1110-1122 "Human cell lines for biopharmaceutical manufacturing: history, current status, and future prospects" lines for biopharmaceutical manufacturing: history, status, and future perspective To ensure complete glycosylation, especially sialic acid addition and tyrosine sulfation, The cell line used for production was designed to express α-2,6-sialyltransferase, which is responsible for tyrosine-O-sulfation. (or both α-2,3- and α-2,6-sialyltransferases) and / or TPST-1 and TPS This can be enhanced by engineering the host cell to co-express the T-2 enzyme.

[0142] 5.5. Biomarkers / Collection / Monitoring Efficiency Efficacy will include cognitive function (e.g., prevention or reduction of neurocognitive decline); CSF and / or a reduction in disease biomarkers (e.g., GAGs) in serum; and / or a reduction in CSF and / or serum This can be monitored by measuring the increase in IDUA enzyme activity in the blood. Symptoms and other safety events can also be monitored.

[0143] (5.5.1. Disease Markers) In one embodiment, the efficacy of treatment with the recombinant vector is determined by measuring the disease progression in the patient. In one embodiment, the method is monitored by measuring the level of a marker. The level of the disease biomarker is measured in the patient's CSF. In one embodiment, The level of the disease biomarker is measured in the serum of the patient. The level of the disease biomarker is measured in the patient's urine. In one embodiment, the disease biomarker is GAG. In one embodiment, the disease biomarker is inflammation. In embodiments, the disease biomarker is a safety event.

[0144] 5.5.2. Neurocognitive Function Tests In one embodiment, the efficacy of treatment with the recombinant vector is evaluated by measuring the level of cognitive function in the patient. Cognitive function is monitored by measuring the level of cognitive function. In one embodiment, cognitive function can be measured by measuring intelligence quotient (IQ). In a specific embodiment, IQ is measured via a validated device for the purpose of Wechsler Abbreviated Scale of Intelligence, 2nd Edition (WASI-I) In one embodiment, cognitive function is measured by a method comprising: In a specific embodiment, memory is measured using a Hopkins Linguistics In one embodiment, cognitive function is measured by the High Viability Learning Test (HVLT). In a specific embodiment, attention is measured via a validated device for attention shift. In one embodiment, cognitive function is measured using IQ, memory, and The measurement is via a validated device for measuring one or more of the following:

[0145] (5.5.3. Physical Changes) In one embodiment, the efficacy of treatment with the recombinant vector is determined by measuring the lysosomal storage The monitoring is performed by measuring physical characteristics associated with the storage deficiency. In one embodiment, the physical characteristic is a reservoir lesion. is short stature. In one embodiment, the physical characteristic is coarsening of facial features. In some embodiments, the physical characteristic is obstructive sleep apnea. In one embodiment, the physical characteristic is hearing impairment. In one embodiment, the physical characteristic is vision impairment. In a specific embodiment, the visual impairment is due to corneal opacity. In one embodiment, the physical characteristic is hydrocephalus. In one embodiment, the physical characteristic is hepatosplenomegaly. In one embodiment, the physical characteristics are bone and joint deformities. The characteristic is valvular heart disease. In some embodiments, the physical characteristic is recurrent upper airway infections. In one embodiment, the physical characteristic is carpal tunnel syndrome. In some embodiments, the physical characteristic is macroglossia (enlarged tongue). The characteristic of the vocal cords is enlargement of the vocal cords and / or a change in voice. Such physical characteristics are well known to those skilled in the art. It can be measured by any method. (Sequence Listing) [Table 2] TIFF2024112876000020.tif221170TIFF2024112876000021.tif220170TIFF2024112876000022.tif218170 TIFF2024112876000023.tif214170TIFF2024112876000024.tif217170TIFF2024112876000025.tif200170

[0146] 6. Working Examples 6.1 Example 1: hIDUA cDNA The hIDUA cDNA-based vector is constructed to contain a transgene containing hIDUA (SEQ ID NO:1). The transgene also contains a signal peptide selected from the group listed in Table 1. Optionally, the vector further comprises a promoter.

[0147] 6.2 Example 2: Substituted hIDUA cDNA 1, which has amino acid substitutions, deletions, or additions compared to the hIDUA sequence of SEQ ID NO:1, e.g. The amino acid sequence may be selected from, but is not limited to, the corresponding non-conserved residues in the orthologues of IDUA shown in FIG. hIDUA cDNA-based vectors containing transgenes, including hIDUA containing the amino acid substitutions to be (wherein such mutations are shown in FIG. 3, which is incorporated herein by reference in its entirety) Incorporated Saito et al., 2014, Mol Genet Metab 111:107-112, 57 MPS I hits or from Table 1, which lists the natural mutations; or each of which is incorporated herein by reference in its entirety. Venturi et al., 2002, Human Mutation #522 Online ("Venturi 2002"), or As reported by Bertola et al., 2011, Human Mutation 32:E2189-E2210 ("Bertola 2011") Identified in reported severe, moderately severe, moderate, or attenuated MPS I phenotypes The transgene must not contain any of the mutations listed in Table 1. Optionally, the vector further comprises a nucleic acid comprising a signal peptide selected from the group consisting of: Contains a promoter.

[0148] 6.3 Example 3: Treatment of MPS I in an Animal Model with hIDUA or Substituted hIDUA When expressed as a transgene, hIDUA cDNA-based vectors are useful for treating MPS I Animal models for MPS I are described, for example, in Clarke et al., 1997, Hum Mol. Genet 6(4):503-511 (mouse); Haskins et al., 1979, Pediatr Res 13(11):1294-97 ( (hybrid domestic cats), Menon et al., 1992, Genomics 14(3):763-768 (dogs), or Shull et al. In the animal model described in the article by I. et al., 1982, Am J Pathol 109(2):244-248 (dogs), The product is delivered to the CSF of the animal. min Sufficient to maintain a concentration of at least 9.25 μg / mL The animals were then intrathecally administered a recombinant vector encoding hIDUA at a dose appropriate for the treatment. The compounds are evaluated for improvement of symptoms consistent with the disease in a particular animal model.

[0149] 6.4 Example 4: Treatment of MPS I with hIDUA or substituted hIDUA When expressed as a transgene, hIDUA cDNA-based vectors are useful for treating MPS I It is believed that the transgene product is delivered to a subject exhibiting MPS I and is expressed in the CSF. min Less The intrathecal administration of hIDUA was performed at a dose sufficient to maintain a concentration of at least 9.25 μg / mL. The cDNA-based vector is administered. After treatment, the subject is evaluated for improvement in symptoms of MPS I. prior to, concurrent with, or subsequent administration of a cDNA-based vector encoding hIDUA. The patient was subsequently administered immunosuppressant medications including rapamycin, MMF, and prednisolone. do.

[0150] 6.5 Example 5: Clinical Protocol for Treatment of MPS I The following examples provide methods for treating human subjects with the rAAV9.hIDUA vector to treat MPS I. This document describes a protocol that can be used to

[0151] Patient population. The patients to be treated are: MPS I confirmed by enzyme activity measured in plasma, fibroblasts or leukocytes diagnosis, Any of the following, if not explainable by any other neurological or psychiatric factors: Early stage neurocognitive decline due to MPS I, defined as: ○ IQ test or one domain of neuropsychological function (verbal comprehension, memory, attention, or perceptual thinking) a score ≥ 1 standard deviation below the mean in Men with documented historical evidence (medical records) of >1 standard deviation decline in sequential testing It may include both sexes or women.

[0152] Patients were included who were receiving a stable regimen of ERT (e.g., ALDURAZYME [laronidase] IV). Women of childbearing potential should have a negative serum pregnancy test on the day of treatment. Sexually active subjects (both female and male) should be medically An approved method of contraception (e.g., condoms, diaphragms, or abstinence) should be used. Patients who may be excluded from intracisternal (IC) therapy include those with contraindications to IC injection or lumbar puncture. Contraindications for IC injection may include any of the following: - A history of previous head / neck surgery that results in a contraindication to IC injections; -Having any contraindication to CT (or contrast) or general anesthesia - have any contraindication to MRI (or gadolinium), Glomerular filtration rate (eGFR) <30mL / min / 1.73m 2 has an estimate of

[0153] Have received IT treatment at any time and experienced a serious adverse reaction thought to be related to IT administration Patients with this condition should not be treated with IC.

[0154] Patients with any condition that the treating physician considers unsuitable for immunosuppressive therapy may not receive treatment. should not be used (e.g., absolute neutrophil count <1.3 × 10 3 / μL, platelet count <100×10 3 / μL, and Hemoglobin <12 g / dL (men) or <10 g / dL (women). Alternative immunosuppressive regimens include sirolimus In any patient with any history of hypersensitivity reaction to muscarin, MMF, or prednisolone It should be used against

[0155] Patients with a history of lymphoma or another cancer other than squamous cell or basal cell carcinoma of the skin are Treatment should not be initiated unless the patient has been in complete remission for at least 3 months prior to treatment.

[0156] Alanine aminotransferase (ALT) or aspartate aminotransferase Patients with aspartate aminotransferase (AST) >3× the upper limit of normal (ULN) or total bilirubin >1.5× the ULN The authors determined that the subject had a history of Gilbert's syndrome and had conjugated bilirubin <35% of total bilirubin. Should not be treated unless known to have a history of fractionated bilirubin .

[0157] Patients with a history of infectious disease or substance abuse are not good candidates for treatment. , history of positive human immunodeficiency virus (HIV) test, active or recurrent hepatitis B or History of hepatitis C or a positive hepatitis B, hepatitis C, or HIV screening test within 1 year prior to treatment A history of alcohol or substance abuse within the past 20 years.

[0158] In one embodiment, the patient is an adult patient. In another embodiment, the patient is a pediatric patient. The patient is a child.

[0159] (Treatment administered - Pretreatment with immunosuppressive therapy) Prior to gene therapy, patients may be administered a immunization therapy to prevent an immune response to the transgene and / or AAV capsid. In order to prevent this, patients should be treated with immunosuppressive therapy. cyclosporine (60 mg once daily, orally, on days -2 to 8), MMF (1 g twice daily, orally, on days -2 to 60), and ciloli mus (6 mg orally on day -2, then 2 mg once daily from day -1 to week 48). The dose of limus should be adjusted to maintain whole blood trough concentrations within the range of 16-24 ng / mL. In subjects, dose adjustments were based on the formula: new dose = current dose × (target concentration / current concentration). Subjects may be administered a small amount of the drug while monitoring concentrations before further dosage adjustments. The new maintenance dose should be continued for at least 7 to 14 days. If the absolute neutrophil count is <1.3 × 10 3 / μL), MMF administration was discontinued or the dose was reduced. It should be.

[0160] Gene therapy. A nonreplicative recombinant AAV serotype 9 capsid containing a hIDUA expression cassette (rAAV9.hIDUA). The AAV9 serotype inhibits the expression of the hIDUA protein in the CNS after IC administration. The vector genome is flanked by AAV2 inverted terminal repeats (ITRs), allowing efficient expression. The expression cassette is driven by a strong constitutive CAG promoter. The rAAV9.hIDUA vector was delivered in Elliott's B solution for intrathecal injection. Suspend.

[0161] rAAV9.hIDUA is administered as a single fixed dose by IC administration: 1.4 x 10 13 GC(1.1×10 10 GC / g brain mass) or a low dose of 7.0 × 10 13 GC(5.6×10 10 A high dose of 5–20 mg / g brain mass was administered. If the patient has neutralizing antibodies to AAV, higher doses can be used. It can be used.

[0162] For administration of rAAV9.IDUA, subjects are placed under general anesthesia. A lumbar puncture is performed and 5 cc of CSF is removed and then contrast IT is injected to aid in visualization of the cisterna magna. CT (with contrast) is used to guide needle insertion and administration of the selected dose of rAAV9.IDUA into the suboccipital space.

[0163] 6.6 Example 6: Clinical Protocol for Treatment of MPS I In the following examples, human subjects are treated with the rAAV9.hIDUA vector to treat MPS I. We describe a protocol that can be used to

[0164] Patient population. The patients to be treated are: MPS I confirmed by enzyme activity measured in plasma, fibroblasts or leukocytes Diagnosis (this includes prior HSCT or prior or current laronidase therapy) (including patients undergoing treatment) Any of the following, if not explainable by any other neurological or psychiatric factors: Early stage neurocognitive decline due to MPS I, defined as: ○ In IQ tests or in one domain of neuropsychological functioning (verbal comprehension, attention, or perceptual reasoning) a score ≥ 1 standard deviation below the mean Males or females aged 6 years or older with a decline of >1 standard deviation on sequential testing.

[0165] Patients must be sufficiently fit to complete the required protocol testing, with or without assistive devices. Have hearing and vision abilities and are willing to wear assistive devices on test day, if applicable It should be obeyed.

[0166] Women of childbearing potential should have a negative serum pregnancy test on the day of treatment. Active subjects were medically permitted to remain vaccinated from screening visit through 24 weeks after vector administration. Sexually active women should be willing to use non-invasive contraceptive methods. Continue effective contraception from the time of consultation until 12 weeks after the last dose of sirolimus (whichever is later). Patients who can be excluded from intracisternal (IC) therapy should be treated with IC injection or intralumbar Contraindications for IC injection may include subjects with any of the following: It may contain: - A history of previous head / neck surgery that results in a contraindication to IC injections; -Having any contraindication to CT (or contrast) or general anesthesia - have any contraindication to MRI (or gadolinium), Glomerular filtration rate (eGFR) <30mL / min / 1.73m 2 has an estimate of

[0167] Have you ever received IT treatment and experienced a serious adverse reaction thought to be related to IT administration? Patients experiencing this condition should not be treated with IC. Patients with any condition that would be considered refractory to treatment should not receive treatment (e.g., absolute neutrophil count <1 .3×10 3 / μL, platelet count <100×10 3 / μL, and hemoglobin <12 g / dL [males] or <10 g / d L [female]. Alternative immunosuppressive regimens include sirolimus, MMF, or overdose to prednisolone. It should be used in any patient with any history of allergic reaction.

[0168] Patients with a history of lymphoma or another cancer other than squamous cell or basal cell carcinoma of the skin are Treatment should not be initiated unless the patient has been in complete remission for at least 3 months prior to treatment.

[0169] Uncontrolled hypertension despite maximal medical therapy (systolic BP >180 mmHg, diastolic BP >180 mmHg) Patients with a BP >100 mmHg) should not be treated.

[0170] Alanine aminotransferase (ALT) or aspartate aminotransferase Patients with aspartate aminotransferase (AST) >3× the upper limit of normal (ULN) or total bilirubin >1.5× the ULN The authors determined that the subject had a history of Gilbert's syndrome and had conjugated bilirubin <35% of total bilirubin. Should not be treated unless known to have a history of fractionated bilirubin .

[0171] Patients with a history of infectious disease or substance abuse are not good candidates for treatment. , history of infection with human immunodeficiency virus (HIV) or hepatitis B or C virus, or Screening for hepatitis B surface antigen or hepatitis B nuclear antibody, or hepatitis C or HIV antibody a positive test result for HIV; a history of alcohol or substance abuse within 1 year prior to screening.

[0172] Patients who received any investigational drug within 30 days or 5 half-lives prior to the start of treatment were IT laronidase can be administered any time in advance, even if the time between administration is long. Treatment should not be initiated unless the patient is diagnosed with

[0173] Pregnant, <6 weeks postpartum, breastfeeding at screening, or any Patients who intend to become pregnant at the time of their intended pregnancy should not be treated.

[0174] Patients with clinically significant ECG abnormalities that jeopardize the subject's safety should not be treated. Patients with serious or unstable medical or psychological conditions that pose a threat to the subject's safety should be treated. isn't it.

[0175] (Treatment administered - Pretreatment with immunosuppressive therapy) Prior to gene therapy, patients may be administered a immunization therapy to prevent an immune response to the transgene and / or AAV capsid. In order to prevent this, patients should be treated with immunosuppressive therapy. cyclosporine (60 mg once daily, orally, on days -2 to 8), MMF (1 g twice daily, orally, on days -2 to 60), and ciloli mus (6 mg orally on day -2, then 2 mg once daily from day -1 to week 48). The dose of limus should be adjusted to maintain whole blood trough concentrations within the range of 16-24 ng / mL. In subjects, dose adjustments were based on the formula: new dose = current dose × (target concentration / current concentration). Subjects may be administered a small amount of the drug while monitoring concentrations before further dosage adjustments. The new maintenance dose should be continued for at least 7 to 14 days.

[0176] The cornerstone of immunosuppressive regimens is the use of corticosteroids to completely suppress the immune system. - Start with IV methylprednisolone for dose loading, followed by oral Prednisolone should be tapered gradually to ensure that patients are off steroids by 12 weeks. Corticosteroid treatment consisted of tacrolimus (24 weeks) and / or sirolimus (12 weeks). Both tacrolimus and sirolimus can be supplemented with MMF. When used, each dose should be adjusted to maintain a blood trough level of 4-8 ng / ml. If only one drug is used, the labeled dose (higher dose) should be used. for example, 0.15 to 0.20 mg / kg given as 2 divided doses every 12 hours. / day tacrolimus; and 1 mg / m 2 / day sirolimus; loading dose, 3 mg / m 2 It should be When MMF is added to the regimen, tacrolimus and / or cilizumab should be used in combination because of their different mechanisms of action. The dose of mus can be maintained.

[0177] Gene therapy. A nonreplicative recombinant AAV serotype 9 capsid containing a hIDUA expression cassette (rAAV9.hIDUA). The AAV9 serotype inhibits the expression of the hIDUA protein in the CNS after IC administration. The vector genome is flanked by AAV2 inverted terminal repeats (ITRs), allowing efficient expression. The expression cassette is driven by a strong constitutive CAG promoter. The rAAV9.hIDUA vector was delivered in Elliott's B solution for intrathecal injection. Suspend.

[0178] rAAV9.hIDUA is administered as a single fixed dose via IC administration: 2×10 9 GC / g brain mass (2.6 ×10 12 GC) or 1 × 10 10 GC / g brain mass (1.3×10 13 The dose is about 5 to 20 ml. The capacity can be set to .

[0179] For administration of rAAV9.IDUA, subjects are placed under general anesthesia.

[0180] 6.7 Example 7: Clinical Protocol for Treatment of MPS I The following examples provide methods for treating human subjects with the rAAV9.hIDUA vector to treat MPS I. This document describes a protocol that can be used to

[0181] Patient population. The patients to be treated are: MPS I confirmed by enzyme activity measured in plasma, fibroblasts or leukocytes Diagnosis (this includes patients who may have previously or currently undergone HSCT or laronidase therapy); Any of the following, if not explainable by any other neurological or psychiatric factors: Early stage neurocognitive decline due to MPS I, defined as: ○ In IQ tests or in one domain of neuropsychological functioning (verbal comprehension, attention, or perceptual reasoning) a score ≥ 1 standard deviation below the mean o Males or females with >1 standard deviation decline in sequential testing.

[0182] Patients must be sufficiently fit to complete the required protocol testing, with or without assistive devices. Have hearing and vision abilities and are willing to wear assistive devices on test day, if applicable It should be obeyed.

[0183] Women of childbearing potential should have a negative serum pregnancy test on the day of treatment. Active subjects were medically permitted to remain vaccinated from screening visit through 24 weeks after vector administration. Sexually active women should be willing to use non-invasive contraceptive methods. Continue effective contraception from the time of consultation until 12 weeks after the last dose of sirolimus (whichever is later). Patients who can be excluded from intracisternal (IC) therapy should be treated with IC injection or intralumbar Contraindications for IC injection may include subjects with any of the following: It may contain: - A history of previous head / neck surgery that results in a contraindication to IC injections; -Having any contraindication to CT (or contrast) or general anesthesia - have any contraindication to MRI (or gadolinium), Glomerular filtration rate (eGFR) <30mL / min / 1.73m 2 has an estimate of

[0184] Have received IT treatment at any time and experienced a serious adverse reaction thought to be related to IT administration Patients with this condition should not be treated with IC. Patients with any condition that may be associated with pulmonary embolism should not receive treatment (e.g., absolute neutrophil count <1.3× 10 3 / μL, platelet count <100×10 3 / μL, and hemoglobin <12 g / dL [male] or <10 g / dL [female] sex]).

[0185] Alternative immunosuppressive regimens include sirolimus or any combination of these for hypersensitivity reactions to prednisolone. It should be used in any patient with a history of primary immunodeficiency, splenectomy or immunosuppression. Patients with a history of any underlying condition that predisposes them to infection should be treated with immunosuppressive therapy. Herpes zoster that has not fully resolved at least 12 weeks prior to screening Infected with the viruses cytomegalovirus or Epstein-Barr virus (EBV) Patients with pulmonary tuberculosis should not be treated with immunosuppressive therapy. Any infection that has not resolved in a timely manner and requires hospitalization or treatment with parenteral anti-infective drugs. or (2) Patients who have been taking oral anti-infective drugs (including anti-viral drugs) within 10 days prior to the second visit. (3) Patients with any active infectious disease or a history of active tuberculosis requiring screening (4) Patients who have a positive Quantiferon_TB Gold test result during the course of treatment, or Patients who have received any live vaccine within 8 weeks prior to signing the consent form, or (5) Patients who underwent major surgery within 8 weeks prior to signing the informed consent, or (6) a study Patients scheduled for major surgery during this time should not be treated with immunosuppressive therapy. Number of balls < 1.3 x 10 3 / μL should not be treated with immunosuppressive therapy.

[0186] Lymphoma or squamous cell carcinoma of the skin unless in complete remission for at least 3 months prior to treatment Patients with a history of another cancer other than follicular or basal cell carcinoma should not be treated.

[0187] Uncontrolled hypertension despite maximal medical therapy (systolic BP >180 mmHg, diastolic BP >180 mmHg) Patients with a BP >100 mmHg) should not be treated.

[0188] Alanine aminotransferase (ALT) or aspartate aminotransferase Patients with aspartate aminotransferase (AST) >3× the upper limit of normal (ULN) or total bilirubin >1.5× the ULN The authors determined that the subject had a history of Gilbert's syndrome and had conjugated bilirubin <35% of total bilirubin. Should not be treated unless known to have a history of fractionated bilirubin .

[0189] Patients with a history of infectious disease or substance abuse are not good candidates for treatment. , history of infection with human immunodeficiency virus (HIV) or hepatitis B or C virus, or Screening for hepatitis B surface antigen or hepatitis B nuclear antibody, or hepatitis C or HIV antibody a positive test result for HIV; a history of alcohol or substance abuse within 1 year prior to treatment.

[0190] In one embodiment, the patient is an adult patient. In another embodiment, the patient is a pediatric patient. It is.

[0191] (Treatment administered - Pretreatment with immunosuppressive therapy) Preventing immune responses to transgenes and / or AAV capsids prior to gene therapy To prevent this, patients should be treated with immunosuppressive therapy. Steroids (methylprednisolone 10 mg / kg intravenously [IV] once on day 1, and Oral prednisone was started at 0.5 mg / kg / day, tapered gradually, and discontinued by week 12. tacrolimus (1 mg twice daily [BID] orally [PO] from week 2 to week 24, to achieve target blood levels (4-8 ng / mL of cyclosporine, tapered over 8 weeks from week 24 to week 32) and Mus (1 mg / m every 4 hours on day -2) 2 ×3 loading dose, followed by sirolimus 0.5 mg on day -1 mg / m 2 / day BID to achieve a target blood level of 4-8 ng / mL for up to 48 weeks Perform a neurological evaluation and monitor tacrolimus / sirolimus blood levels. Doses of rolimus and tacrolimus are adjusted to maintain blood levels in the target range. After 48 weeks, no immunosuppressive therapy is planned. In most subjects, dose adjustments will be The new dose can be based on: new dose = current dose x (target concentration / current concentration). The subject can further Before adjusting the dosage, administer the new drug for at least 7 to 14 days while monitoring concentrations. A low maintenance dose should be continued.

[0192] Gene therapy. A nonreplicative recombinant AAV serotype 9 capsid containing a hIDUA expression cassette (rAAV9.hIDUA). The AAV9 serotype inhibits the expression of the hIDUA protein in the CNS after IC administration. The vector genome is flanked by AAV2 inverted terminal repeats (ITRs), allowing efficient expression. The expression cassette is driven by a strong constitutive CAG promoter. The rAAV9.hIDUA vector was delivered in Elliott's B solution for intrathecal injection. Suspend.

[0193] rAAV9.hIDUA is administered as a single fixed dose via IC administration: 2×10 9 GC / g brain mass (2.6 ×10 12 GC) or 1 × 10 10 GC / g brain mass (1.3×10 13 The dose is about 5 to 20 ml. The capacity can be set to .

[0194] For administration of rAAV9.IDUA, subjects are placed under general anesthesia.

[0195] 6.8 Example 8: Clinical Protocol for Treatment of MPS I The following examples provide methods for treating human subjects with the rAAV9.hIDUA vector to treat MPS I. This document describes a protocol that can be used to

[0196] Patient population. The patients to be treated are: MPS I confirmed by enzyme activity measured in plasma, fibroblasts or leukocytes Diagnosis (this includes patients who may have previously or currently undergone HSCT or laronidase therapy); Any of the following, if not explainable by any other neurological or psychiatric factors: Early neurocognitive deficits due to MPS I defined as: ○ In IQ tests or in one domain of neuropsychological functioning (verbal comprehension, attention, or perceptual reasoning) a score ≥ 1 standard deviation below the mean Males or females aged 6 years or older with a decline of >1 standard deviation on sequential testing.

[0197] Patients must be sufficiently fit to complete the required protocol testing, with or without assistive devices. Have hearing and vision abilities and are willing to wear assistive devices on test day, if applicable It should be obeyed.

[0198] Women of childbearing potential should have a negative serum pregnancy test on the day of treatment. Active subjects were medically permitted to remain vaccinated from screening visit through 24 weeks after vector administration. Sexually active women should be willing to use non-invasive contraceptive methods. Continue effective contraception from the time of consultation until 12 weeks after the last dose of sirolimus (whichever is later). Patients who can be excluded from intracisternal (IC) therapy should be treated with IC injection or intralumbar Contraindications for IC injection may include subjects with any of the following: It may contain: - A history of previous head / neck surgery that results in a contraindication to IC injections; -Having any contraindication to CT (or contrast) or general anesthesia - have any contraindication to MRI (or gadolinium), Glomerular filtration rate (eGFR) <30mL / min / 1.73m 2 has an estimate of

[0199] Have received IT treatment at any time and experienced a serious adverse reaction thought to be related to IT administration Patients with this condition should not be treated with IC. Patients with any condition that may be associated with pulmonary embolism should not receive treatment (e.g., absolute neutrophil count <1.3× 10 3 / μL, platelet count <100×10 3 / μL, and hemoglobin <12 g / dL [male] or <10 g / dL [female] sex]).

[0200] Alternative immunosuppressive regimens include overdose to tacrolimus, sirolimus, or prednisolone. It should be used in any patient with any history of hypersensitivity reactions. Patients with a history of splenectomy or any underlying condition that predisposes to infection should be immunosuppressed. should not be treated with treatment. Not herpes zoster virus, cytomegalovirus or Epstein-Barr virus (EBV Patients infected with HIV should not be treated with immunosuppressive therapy. Any symptom that has not resolved within the last 8 weeks and requires hospitalization or treatment with parenteral anti-infective drugs (2) Patients with a suspected infection or (3) those who had taken oral anti-infective drugs (antivirals) within 10 days prior to the second visit Patients with any active infection requiring treatment with anti-cancer drugs (including anti-cancer drugs) or a history of active tuberculosis; or (3) a positive Quantiferon_TB Gold test result during screening; or (4) Patients who had received any live vaccine within 8 weeks prior to signing the informed consent form or (5) Patients who have undergone major surgery within 8 weeks prior to signing the informed consent. or (6) patients scheduled for major surgery during the study period should not be treated with immunosuppressive therapy. Absolute neutrophil count <1.3 × 10 3 / μL should not be treated with immunosuppressive therapy. .

[0201] Patients with a history of lymphoma or another cancer other than squamous cell or basal cell carcinoma of the skin are Treatment should not be initiated unless the patient has been in complete remission for at least 3 months prior to treatment.

[0202] Uncontrolled hypertension despite maximal medical therapy (systolic BP >180 mmHg, diastolic BP >180 mmHg) Patients with a BP >100 mmHg) should not be treated.

[0203] Alanine aminotransferase (ALT) or aspartate aminotransferase Patients with aspartate aminotransferase (AST) >3× the upper limit of normal (ULN) or total bilirubin >1.5× the ULN The authors determined that the subject had a history of Gilbert's syndrome and had conjugated bilirubin <35% of total bilirubin. Should not be treated unless known to have a history of fractionated bilirubin .

[0204] Patients with a history of infectious disease or substance abuse are not good candidates for treatment. , history of infection with human immunodeficiency virus (HIV) or hepatitis B or C virus, or Screening for hepatitis B surface antigen or hepatitis B nuclear antibody, or hepatitis C or HIV antibody a positive test result for HIV; a history of alcohol or substance abuse within 1 year prior to treatment.

[0205] (Treatment administered - Pretreatment with immunosuppressive therapy) Preventing immune responses to transgenes and / or AAV capsids prior to gene therapy To prevent this, patients should be treated with immunosuppressive therapy. Steroids (methylprednisolone 10 mg / kg intravenously [IV] once on day 1, and Oral prednisone was started at 0.5 mg / kg / day, tapered gradually, and discontinued by week 12. tacrolimus (1 mg twice daily [BID] orally [PO] from Week 2 to Week 24, to achieve target blood levels (4-8 ng / mL of cyclosporine, tapered over 8 weeks from week 24 to week 32) and Mus (1 mg / m every 4 hours on day -2) 2 ×3 loading dose, followed by sirolimus 0.5 mg on day -1 mg / m 2 / day BID to achieve a target blood level of 4-8 ng / ml for up to 48 weeks Perform a neurological evaluation and monitor tacrolimus / sirolimus blood levels. Doses of rolimus and tacrolimus are adjusted to maintain blood levels in the target range. After 48 weeks, no immunosuppressive therapy is planned. In most subjects, dose adjustments will be The new dose can be based on: new dose = current dose x (target concentration / current concentration). The subject can further Before adjusting the dosage, administer the new drug for at least 7 to 14 days while monitoring concentrations. A low maintenance dose should be continued.

[0206] Gene therapy. A nonreplicative recombinant AAV serotype 9 capsid containing a hIDUA expression cassette (rAAV9.hIDUA). The AAV9 serotype inhibits the expression of the hIDUA protein in the CNS after IC administration. The vector genome is flanked by AAV2 inverted terminal repeats (ITRs), allowing efficient expression. The expression cassette is driven by a strong constitutive CAG promoter. The rAAV9.hIDUA vector was delivered in Elliott's B solution for intrathecal injection. Suspend.

[0207] rAAV9.hIDUA is administered as a single fixed dose via IC administration: 2×10 9 GC / g brain mass (2.6 ×10 12 GC) or 1 × 10 10 GC / g brain mass (1.3×10 13 The dose is about 5 to 20 ml. The capacity can be set to .

[0208] For administration of rAAV9.IDUA, subjects are placed under general anesthesia.

[0209] 6.9 Example 9: Clinical Protocol for Treatment of MPS I The following examples provide methods for treating human subjects with the rAAV9.hIDUA vector to treat MPS I. This document describes a protocol that can be used to

[0210] Patient population. The patients to be treated are: MPS I confirmed by enzyme activity measured in plasma, fibroblasts or leukocytes Diagnosis (this includes patients who may have previously or currently undergone HSCT or laronidase therapy); Any of the following, if not explainable by any other neurological or psychiatric factors: Early neurocognitive deficits due to MPS I defined as: ○ In IQ tests or in one domain of neuropsychological functioning (verbal comprehension, attention, or perceptual reasoning) a score ≥ 1 standard deviation below the mean ○ have a reduction of >1 standard deviation in sequential testing, A new study has shown that patients under the age of 3 years experience Hurler syndrome, which is associated with neurocognitive decline. ≥ 6 years of age with a severe form of MPS I (Hurler syndrome) confirmed by a rare mutation(s) This may include males or females aged 18 or over and males or females under 3 years of age.

[0211] Patients must be sufficiently fit to complete the required protocol testing, with or without assistive devices. Have hearing and vision abilities and are willing to wear assistive devices on test day, if applicable It should be obeyed.

[0212] Women of childbearing potential should have a negative serum pregnancy test on the day of treatment. Active subjects were medically permitted to remain vaccinated from screening visit through 24 weeks after vector administration. Sexually active women should be willing to use non-invasive contraceptive methods. Continue effective contraception from the time of consultation until 12 weeks after the last dose of sirolimus (whichever is later). Patients who can be excluded from intracisternal (IC) therapy should be treated with IC injection or intralumbar Contraindications for IC injection may include subjects with any of the following: It may contain: - A history of previous head / neck surgery that results in a contraindication to IC injections; -Having any contraindication to CT (or contrast) or general anesthesia - have any contraindication to MRI (or gadolinium), Glomerular filtration rate (eGFR) <30mL / min / 1.73m 2 has an estimate of

[0213] Have received IT treatment at any time and experienced a serious adverse reaction thought to be related to IT administration Patients with this condition should not be treated with IC. Patients with any condition that may be associated with pulmonary embolism should not receive treatment (e.g., absolute neutrophil count <1.3× 10 3 / μL, platelet count <100×10 3 / μL, and hemoglobin <12 g / dL [male] or <10 g / dL [female] sex]).

[0214] Alternative immunosuppressive regimens include overdose to tacrolimus, sirolimus, or prednisolone. Should be used in any patient with any history of hypersensitivity reactions or should such patients be excluded. Patients with primary immunodeficiency, splenectomy, or any underlying condition that predisposes to infection should be screened. Patients with a history of the condition should not be treated with immunosuppressive therapy. Herpes zoster virus, cytomegalovirus, or Patients infected with Epstein-Barr virus (EBV) are treated with immunosuppressive therapy. (1) The symptoms have not resolved at least 8 weeks before the second visit and the symptoms have not been resolved due to hospitalization or parental Patients with any infection requiring treatment with anti-infective drugs, or (2) patients who were diagnosed with Any active infection requiring oral anti-infectives (including antivirals) within 0 days, or or (3) patients with a history of active tuberculosis, or (4) those who received Quantiferon_TB Gol during screening. d) Patients who have had a positive test result, or (4) Patients who have had a positive test result within 8 weeks prior to signing the informed consent form. (5) Patients who have received any live vaccine within the past 12 months or who have signed an informed consent form (6) Patients who have undergone major surgery within the previous 8 weeks or who are scheduled to undergo major surgery during the study period should not be treated with immunosuppressive therapy. Absolute neutrophil count <1.3 × 10 3 Patients with ≥ 100 μL / μL were It should not be treated with suppressive therapy.

[0215] Patients with a history of lymphoma or another cancer other than squamous cell or basal cell carcinoma of the skin are Treatment should not be initiated unless the patient has been in complete remission for at least 3 months prior to treatment.

[0216] Uncontrolled hypertension despite maximal medical therapy (systolic BP >180 mmHg, diastolic BP >180 mmHg) Patients with a BP >100 mmHg) should not be treated.

[0217] Alanine aminotransferase (ALT) or aspartate aminotransferase Patients with aspartate aminotransferase (AST) >3× the upper limit of normal (ULN) or total bilirubin >1.5× the ULN The authors determined that the subject had a history of Gilbert's syndrome and had conjugated bilirubin <35% of total bilirubin. Should not be treated unless known to have a history of fractionated bilirubin .

[0218] Patients with a history of infectious disease or substance abuse are not good candidates for treatment. , history of infection with human immunodeficiency virus (HIV) or hepatitis B or C virus, or Screening for hepatitis B surface antigen or hepatitis B nuclear antibody, or hepatitis C or HIV antibody a positive test result for HIV; a history of alcohol or substance abuse within 1 year prior to treatment.

[0219] (Treatment administered - Pretreatment with immunosuppressive therapy) Preventing immune responses to transgenes and / or AAV capsids prior to gene therapy For patients aged 6 years or older, such patients should be treated with immunosuppressive therapy. Immunosuppressive treatment consisted of corticosteroids (methylprednisolone 10 mg / kg intravenously once on day 1 [ IV], and oral prednisone was started on day 2 at 0.5 mg / kg / day and tapered gradually. and discontinued by week 12), tacrolimus (1 mg orally twice daily [BID] from week 2 to week 24 PO, with a target blood level of 4-8 ng / mL for 8 weeks from Week 24 to Week 32. tapered), and sirolimus (1 mg / m every 4 hours on day -2) 2 ×3 loading dose, followed by Sirolimus 0.5 mg / m on day -1 2 / day BID, target blood levels of 4-8 ng / day until week 48 For patients under the age of 3, such immunosuppressive therapy includes corticosteroids. Steroids (methylprednisolone 10 mg / kg intravenously [IV] once on day 1, and Oral prednisone was started at 0.5 mg / kg / day, tapered gradually, and discontinued by week 12. tacrolimus (0.05 mg / kg twice daily [BID] orally [PO] from Week 2 to Week 24, with a target blood glucose level of 1.0 mg / kg / day or 0.05 ... a mid-level of 2-4 ng / mL, tapered over 8 weeks from weeks 24 to 32; and Sirolimus (1 mg / m every 4 hours on day -2) 2 ×3 loading doses, followed by sirolimus from day -1 0.5 mg / m 2 / day BID to achieve a target blood level of 1-3 ng / ml for up to 48 weeks) Perform a neurological evaluation and monitor tacrolimus / sirolimus blood levels. Doses of sirolimus and tacrolimus are adjusted to maintain blood levels in the target range. After 48 weeks, no immunosuppressive therapy is planned. Dose adjustments are not required in most subjects. can be based on the formula: New Dose = Current Dose x (Target Concentration / Current Concentration). Monitor concentrations for at least 7 to 14 days before further dosage adjustments. The new maintenance dose should be continued.

[0220] Gene therapy. A nonreplicative recombinant AAV serotype 9 capsid containing a hIDUA expression cassette (rAAV9.hIDUA). The AAV9 serotype inhibits the expression of the hIDUA protein in the CNS after IC administration. The vector genome is flanked by AAV2 inverted terminal repeats (ITRs), allowing efficient expression. The expression cassette is driven by a strong constitutive CAG promoter. The rAAV9.hIDUA vector was delivered in Elliott's B solution for intrathecal injection. Suspend.

[0221] For patients 6 years of age and older, rAAV9.hIDUA will be administered as a single fixed dose via IC administration: 2 ×10 9 GC / g brain mass (2.6×10 12 GC) or 1 × 10 10 GC / g brain mass (1.3×10 13 GC) dosage The dose may be up to about 5 ml in volume.

[0222] For patients younger than 3 years, rAAV9.hIDUA was administered IC at a dose of 1 × 10 10 At a dose of GC / g brain mass (4 months 6.0 × 10 for patients aged 10 years or older but under 9 months 12 GC; 9 months or older but not older than 18 months 1.0 × 10 for patients under 1 year of age 13 GC; 1.1 for patients aged 18 months or older but less than 3 years ×10 13 GC), or 5 × 10 10 At a dose of GC / g brain mass (patients aged 4 months or older but less than 9 months) About 3.0 x 10 13 GC; 5.0 × 10 for patients aged 9 months or older but less than 18 months 13 GC; 5.5 × 10 for patients aged 18 months or older but less than 3 years 13 GC) as a single fixed dose The dose may be in a volume of about 5 ml or less.

[0223] For administration of rAAV9.IDUA, subjects are placed under general anesthesia.

[0224] 6.10 Example 10: Clinical Protocol for Treatment of MPS I The following examples provide methods for treating human subjects with the rAAV9.hIDUA vector to treat MPS I. This document describes a protocol that can be used to

[0225] Patient population. The patients to be treated are: Clinical signs and symptoms consistent with MPS IH and / or abrupt changes associated with only a severe phenotype Severe, as determined by the presence of homozygosity or compound heterozygosity for a mutation Diagnosis of MPS I-Hurler, may include males or females under the age of 3 with an intelligence quotient (IQ) score of ≧55.

[0226] Patients must be sufficiently fit to complete the required protocol testing, with or without assistive devices. Have hearing and vision abilities and are willing to wear assistive devices on test day, if applicable It should be obeyed.

[0227] Patients who may be excluded from intracisternal (IC) therapy include those with contraindications to IC injection or lumbar puncture. Contraindications for IC infusion may include any of the following: - A history of previous head / neck surgery that results in a contraindication to IC injections; -Having any contraindication to CT (or contrast) or general anesthesia - have any contraindication to MRI (or gadolinium), Glomerular filtration rate (eGFR) <30mL / min / 1.73m 2 has an estimate of

[0228] Have received IT treatment at any time and experienced a serious adverse reaction thought to be related to IT administration Patients with this condition should not be treated with IC. Patients with any condition that may be associated with pulmonary embolism should not receive treatment (e.g., absolute neutrophil count <1.3× 10 3 / μL, platelet count <100×10 3 / μL), and hemoglobin is assessed.

[0229] Alternative immunosuppressive regimens include overdose to tacrolimus, sirolimus, or prednisolone. Should be used in any patient with any history of hypersensitivity reactions or should such patients be excluded. Patients with primary immunodeficiency, splenectomy, or any underlying condition that predisposes to infection should be screened. Patients with a history of the condition should not be treated with immunosuppressive therapy. Herpes zoster virus, cytomegalovirus, or Patients infected with Epstein-Barr virus (EBV) are treated with immunosuppressive therapy. (1) The symptoms have not resolved at least 8 weeks before the second visit and the symptoms have not been resolved due to hospitalization or parental Patients with any infection requiring treatment with anti-infective drugs, or (2) patients who were diagnosed with Any active infection requiring oral anti-infectives (including antivirals) within 0 days, or or (3) patients with a history of active tuberculosis, or (4) those who received Quantiferon_TB Gol during screening. d) Patients who have had a positive test result, or (4) Patients who have had a positive test result within 8 weeks prior to signing the informed consent form. (5) Patients who have received any live vaccine within the past 12 months or who have signed an informed consent form (6) Patients who have undergone major surgery within the previous 8 weeks or who are scheduled to undergo major surgery during the study period should not be treated with immunosuppressive therapy. Absolute neutrophil count <1.3 × 10 3 Patients with ≥ 100 μL / μL were It should not be treated with suppressive therapy.

[0230] Patients with a history of lymphoma or another cancer other than squamous cell or basal cell carcinoma of the skin are Treatment should not be initiated unless the patient has been in complete remission for at least 3 months prior to treatment.

[0231] Uncontrolled hypertension despite maximal medical therapy (systolic BP >180 mmHg, diastolic BP >180 mmHg) Patients with a BP >100 mmHg) should not be treated.

[0232] Alanine aminotransferase (ALT) or aspartate aminotransferase Patients with aspartate aminotransferase (AST) >3× the upper limit of normal (ULN) or total bilirubin >1.5× the ULN The person in charge should not, unless the subject is known to have a history of Gilbert's syndrome, It should not be treated.

[0233] Patients with a history of infectious disease or substance abuse are not good candidates for treatment. , history of infection with human immunodeficiency virus (HIV) or hepatitis B or C virus, or Screening for hepatitis B surface antigen or hepatitis B nuclear antibody, or hepatitis C or HIV antibody a positive test result for HIV; a history of alcohol or substance abuse within 1 year prior to treatment.

[0234] (Treatment administered - Pretreatment with immunosuppressive therapy) Preventing immune responses to transgenes and / or AAV capsids prior to gene therapy Patients should be treated with immunosuppressive therapy to prevent pulmonary embolism. Prednisone dosage is 0.5 mg / kg / dose. The dose of tacrolimus will be tapered starting from day 1 of treatment and continuing until the Week 12 visit. Adjust the dose to maintain the trough concentration in whole blood within 2-4 ng / mL for 24 weeks. At week 28, the dose is further reduced by approximately 50%. Tacrolimus will be discontinued at week 32. The dose of sirolimus will be adjusted to maintain whole blood trough concentrations of 1-3 ng / mL. Dose adjustments will be adjusted to maintain the dose within 1 mL of normal. For most subjects, dose adjustments will be performed according to the formula: New Dose = The dose can be based on current dose x (target concentration / current concentration). The subject may then adjust the dosage. Before adjusting to a new maintenance dose, monitor concentrations for at least 7 to 14 days. For further details, see below.

[0235] (Corticosteroids)

[0236] On the morning of vector administration (Day 1, pre-administration), patients were administered methi Give ruprednisolone 10 mg / kg (maximum 500 mg) IV. Methylprednisolone is given IP lumbar. Should be administered prior to vertebral puncture and IC injection. Premedication with acetaminophen will be optional at the discretion of the investigator.

[0237] Oral prednisone on day 2 with the goal of discontinuing prednisone by week 12 Prednisone doses are as follows: Day 2 to the end of week 2: 0.5 mg / kg / day Weeks 3 and 4: 0.35 mg / kg / day Weeks 5-8: 0.2 mg / kg / day Weeks 9-12: 0.1 mg / kg. Prednisone was discontinued after week 12. The exact dose of prednisone was increased by one level. The dose can be adjusted to a clinically practical level.

[0238] (Sirolimus)

[0239] Two days before vector administration (day -2): 1 mg / m every 4 hours 2 ×3 loading doses of sirolimus Administer.

[0240] Day -1: 0.5 mg / m2 divided into two doses per day with a target blood level of 1-3 ng / ml 2 / Sirolimus for days.

[0241] Sirolimus will be discontinued after the Week 48 visit.

[0242] (Tacrolimus)

[0243] Tacrolimus was started on day 2 (the day after IP administration) at a dose of 0.05 mg / kg twice daily for 24 weeks. The dose was adjusted to achieve a blood level of 2 to 4 ng / mL over time.

[0244] Tacrolimus will be started at the week 24 visit and tapered over 8 weeks. The dose is reduced by approximately 50%. At week 28, the dose is reduced again by approximately 50%. It will be discontinued at week 32.

[0245] Gene therapy. A nonreplicative recombinant AAV serotype 9 capsid containing a hIDUA expression cassette (rAAV9.hIDUA). The AAV9 serotype inhibits the expression of the hIDUA protein in the CNS after IC administration. The vector genome is flanked by AAV2 inverted terminal repeats (ITRs), allowing efficient expression. The expression cassette is driven by a strong constitutive CAG promoter. The rAAV9.hIDUA vector was delivered in Elliott's B solution for intrathecal injection. Suspend.

[0246] rAAV9.hIDUA was administered IC at 1 × 10 10 At a dose of GC / g brain mass (4 months or older but not 9 months) 6.0 × 10 for patients under 2 years of age 12 GC: For patients aged 9 months or older but less than 18 months is 1.0×10 13 GC; 1.1 × 10 for patients aged 18 months or older but less than 3 years 13 GC), or 5 ×10 10 At a dose of GC / g brain mass (3.0 × 10 for patients aged 4 months or older but less than 9 months) 1 3 GC; 5.0 × 10 for patients aged 9 months or older but less than 18 months 13 GC: 18 months or older However, for patients under 3 years of age, 5.5 × 10 13 GC), administered as a single fixed dose. The dose is , the volume may be about 5 to 20 ml.

[0247] For administration of rAAV9.IDUA, subjects are placed under general anesthesia.

[0248] (Equivalent) Although the present invention has been described in detail with reference to specific embodiments thereof, it should be understood that the present invention is not limited to the above embodiments. It will be understood that various modifications are within the scope of the present invention. In addition to the invention illustrated and described, various modifications of the invention will become apparent from the foregoing specification and accompanying drawings. Such modifications will be apparent to those skilled in the art and are intended to fall within the scope of the appended claims. It is intended that those skilled in the art will be able to readily understand the specific embodiments of the invention described herein. Recognize or use within the bounds of routine experimentation many equivalents of Such equivalents are intended to be encompassed by the following claims. .

[0249] All publications, patents, and patent applications mentioned in this specification are individually incorporated by reference. It is specifically and specifically stated that a patent or patent application is incorporated by reference in its entirety herein. The same disclosures are incorporated herein by reference as if set forth separately. There are.

Claims

1. A pharmaceutical composition for treating a human subject diagnosed with Mucopolysaccharidosis Type I (MPS I), comprising a recombinant expression vector comprising a CB7 promoter and an expression cassette encoding human alpha-L-iduronidase (IDUA), the human subject is 18 years of age or younger; the pharmaceutical composition is for single administration via intracisternal (IC) injection, intracerebroventricular (ICV) injection, or lumbar puncture to the human subject; a single administration of the pharmaceutical composition is sufficient to treat the human subject; and The pharmaceutical composition, wherein glycosylated recombinant human IDUA is produced by human neuronal cells or human glial cells after the pharmaceutical composition is administered to the human subject.

2. The pharmaceutical composition of claim 1, wherein the glycosylated recombinant human IDUA is delivered to the cerebrospinal fluid of the brain of the human subject.

3. The pharmaceutical composition is 6.0×10 12 GC, 1.0×10 13 GC, 1.1 × 10 13 GC, 3.0×10 13 GC, 5.0×10 13 GC or 5.5×10 13 3. The pharmaceutical composition according to claim 1 or 2, for administration in a dose of GC.

4. The pharmaceutical composition is 9 GC / g brain mass ~5×10 10 3. The pharmaceutical composition of claim 1 or 2, for administration at doses spanning the range of GC / g brain mass.

5. The pharmaceutical composition of any one of claims 1 to 4, wherein the human subject is 4 months of age or older.

6. The pharmaceutical composition of any one of claims 1 to 4, wherein the human subject is under 3 years of age.

7. The pharmaceutical composition according to any one of claims 1 to 6, wherein the recombinant expression vector is a recombinant adeno-associated virus (AAV) vector.

8. The pharmaceutical composition of claim 7, wherein the recombinant AAV vector comprises an AAV9 capsid protein or a recombinant AAV9 capsid protein.

9. The pharmaceutical composition of claim 7, wherein the recombinant AAV vector comprises an AAVrh10 capsid protein or a recombinant AAVrh10 capsid protein.

10. The pharmaceutical composition of any one of claims 1 to 9, wherein the human IDUA comprises SEQ ID NO:

1.

11. The pharmaceutical composition according to any one of claims 1 to 10, wherein an immunosuppressive treatment is administered to the human subject prior to or simultaneously with the pharmaceutical composition, and the composition is designed to continue the immunosuppressive treatment thereafter.

12. 12. The pharmaceutical composition of claim 11, wherein the immunosuppressive treatment comprises administering to the human subject a combination of (a) tacrolimus and mycophenolic acid, (b) rapamycin and mycophenolic acid, or (c) tacrolimus, rapamycin, and a corticosteroid.

13. 13. The pharmaceutical composition of claim 11 or 12, wherein the immunosuppressive treatment is discontinued after 180 days.

14. 14. The pharmaceutical composition of claim 12 or 13, wherein the corticosteroid is prednisolone, methylprednisolone, or a combination thereof.

15. 15. The pharmaceutical composition of any one of claims 1 to 14, wherein the human subject has previously undergone hematopoietic stem cell transplantation (HSCT) and / or enzyme replacement therapy (ERT) treatment prior to the first administration of the pharmaceutical composition to the human subject.

16. The pharmaceutical composition of any one of claims 1 to 15, wherein the human subject has severe MPS I.